EP1039801A1 - 207 menschliche sekretierte proteine - Google Patents

207 menschliche sekretierte proteine

Info

Publication number
EP1039801A1
EP1039801A1 EP98926237A EP98926237A EP1039801A1 EP 1039801 A1 EP1039801 A1 EP 1039801A1 EP 98926237 A EP98926237 A EP 98926237A EP 98926237 A EP98926237 A EP 98926237A EP 1039801 A1 EP1039801 A1 EP 1039801A1
Authority
EP
European Patent Office
Prior art keywords
gene
polypeptides
tissue
seq
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98926237A
Other languages
English (en)
French (fr)
Other versions
EP1039801A4 (de
Inventor
Paul Young
John Greene
Ann M. Ferrie
Steven Ruben
Craig Rosen
Jing-Shan Hu
Henrik Olsen
Reinhard Ebner
Laurie A. Brewer
Paul A. Moore
Yanggu E Shi
Charles Florence
Kimberly Florence
David Lafleur
Jian Ni
Ping Fan
Ying-Fei Wei
Carrie Fischer
Daniel Soppet
Yi Li
Zizhen ZENG
Hla Kyaw
Guo-Liang Yu
Ping Feng
Patrick Dillon
Gregory ENDRESS
Kenneth Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP04001119A priority Critical patent/EP1428833A3/de
Publication of EP1039801A1 publication Critical patent/EP1039801A1/de
Publication of EP1039801A4 publication Critical patent/EP1039801A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.
  • bacterium which exist as a single compartment surrounded by a membrane
  • human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments.
  • Each membrane-bounded compartment, or organelle contains different proteins essential for the function of the organelle.
  • the cell uses "sorting signals ' which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.
  • One type of sorting signal directs a class of proteins to an organelle called the endoplasmic reticulum (ER).
  • ER endoplasmic reticulum
  • the ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus.
  • the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles. Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein.
  • vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.
  • the present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.
  • isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
  • an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
  • a "secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.
  • a "polynucleotide” refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC.
  • the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.
  • a "polypeptide” refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.
  • the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis).
  • a representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number.
  • the ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA.
  • the ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.
  • a “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC.
  • Stringent hybridization conditions refers to an overnight incubation at 42°
  • nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
  • washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
  • blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
  • the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
  • polynucleotide which hybridizes only to poly A + sequences (such as any 3' terminal poly A + tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
  • the polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double- stranded regions.
  • the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • polynucleotide embraces chemically, enzymatically, or metabolically modified forms.
  • the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
  • the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini.
  • polypeptides may be branched , for example, as a result of ubiquitinafion, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitinafion. (See,
  • SEQ ID NO:X refers to a polynucleotide sequence while “SEQ ID NO: Y” refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.
  • a polypeptide having biological activity refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer, disorders of neural crest derived cells including pigmentation defects, melanoma, reproductive organ defects, and defects of the kidney.
  • diseases and conditions include, but are not limited to, cancer, disorders of neural crest derived cells including pigmentation defects, melanoma, reproductive organ defects, and defects of the kidney.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the skin, reproductive, and renal systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating disorders that arise from alterations in the number or fate of neural crest derived cells including cancers such as melanoma and defects of the developing reproductive system.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental disorders of the brain or lung.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous and pulmonary systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing disorders associated with abnormal proliferation of cells in the Central nervous system and developing lung.
  • This gene is expressed primarily in breast lymph node and to a lesser extent in ovarian cancer and chondrosarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune responses such as inflammation or immune surveillance for tumors. This gene may be important for inflammatory responses associated with tumors.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 236 as residues: Lys-45 to Val-50, Lys-69 to Arg-76.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of immune responses including those associated with tumor-induced inflammation.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, i munilogical diseases involving T-cells such as inflammation, autoimmunity, and cancers including T-cell lymphomas.
  • diseases and conditions include, but are not limited to, i munilogical diseases involving T-cells such as inflammation, autoimmunity, and cancers including T-cell lymphomas.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of T-cells and other cells of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating T-cell based disorders such as inflammatory diseases, autoimmune disease and tumors including T-cell lymphomas.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation, autoimmunity, infection, or disorders involving activation of monocytes.
  • diseases and conditions which include, but are not limited to, inflammation, autoimmunity, infection, or disorders involving activation of monocytes.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 238 as residues: Asp- 19 to Arg-31.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing or treating diseases that result in activation of monocytes including infections, inflammatory responses or autoimmune diseases.
  • the translation product of this gene shares sequence homology with terminal deoxynucleotidyltransferase which is thought to be important in catalyzing the elongation of oligo- or polydeoxynucleotide chains.
  • This gene is expressed primarily in activated human neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly those of the blood such as leukemia and deficiencies in neutrophils such as neutropenia.
  • diseases and conditions which include, but are not limited to, cancer, particularly those of the blood such as leukemia and deficiencies in neutrophils such as neutropenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the cardiovascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to terminal deoxynucleotidyltransferase indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and differential diagnosis of acute leukemia's.
  • this gene may function in the proliferation of neutrophils and be useful as a treatment for neutropenia, for example, following neutropenia as a result of chemotherapy.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • diseases and conditions which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • diseases and conditions which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 241 as residues: Ser-14 to Pro-22, Leu-43 to Val-53.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • diseases and conditions which include, but are not limited to, diseases of the immune system, including inflammatory diseases and allergies.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 242 as residues: Tyr-22 to His-35.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the immune system since expression is primarily in neutrophils, and may be useful as a growth factor for the differentiation or proliferation of neutrophils for the treatment of neutropenia following chemotherapy.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune dysfunctions including cancer of the T lymphocytes and autoimmune disorders and inflammation.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of immune disorders particularly of T-cell origin and may act as a growth factor for particular subsets of T- cells such as CD4 positive cells which would make this a useful therapeutic for the treatment of HIV and other immune compromising illnesses.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of many developmental abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the developing fetus
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor or differentiation factor for particular cell types in the developing fetus and may be useful in replacement or other types of therapy in cases where the gene is expressed aberrantly.
  • This gene is expressed primarily in T-cells and to a lesser extent in tumor tissue including glioblastoma, meningioma, and Wilm's tumor.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the immune system including autoimmune conditions such as rheumatoid arthritis, inflammatory disorders and cancer.
  • diseases and conditions which include, but are not limited to, diseases of the immune system including autoimmune conditions such as rheumatoid arthritis, inflammatory disorders and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 245 as residues: Thr-9 to Ser-14.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis/ modulation of immune function disorders, including rheumatoid arthritis and inflammatory responses.
  • This gene is expressed primarily in placenta and to a lesser extent in fetal liver and bone marrow.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of hematological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematological and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematapoietic stem cells or progenitor cells in the treatment of chemotherapy patients or kidney disease.
  • This gene is expressed primarily in stromal cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of hematapoietic disorders including cancer, neutropenia, anemia, and thrombocytopenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematapoietic and immune
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematapoietic stem cells or progenitor cells, in particular following chemotherapy treatment.
  • polypeptides encoded by this gene comprise the following amino acid sequences: MAPPAPGPASGGSGEVDELFDVKNAFYIGSYQQCINEAXXVK-LSSPERDVERD V-FLYRAYLAQRKFGVVLDEIKPSSAPELQAVRMFADYLAHESRRDSIVAELDRE MSRSXDVTNTT- ⁇ LMAASIYLHDQNPDAALRALHQGDSLECTAMTVQ-LLKLD RLDLAR-KELK-RMQDLDEDAT---TQLATAWVSLATGGE--LQDAYYIFQE I ⁇ LLLLNGQ-AACHMAQGRWEAAEGLLQEALDKDSGYPETLVNLIVLSQHLGKP PEVTNRYLSQLK
  • This gene is expressed primarily in activated monocytes and T-cells, and to a lesser extent in multiple other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunomodulation, specifically relating to transport problems in these cells.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to epsilon-COP indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating /diagnosing problems with the cellular transport of proteins that may result in immunologic dysfunction.
  • the translation product of this gene shares sequence homology with an RNA helicase which is thought to be important in polynucleotide metabolism.
  • the translation product of this contig exhibits good homology to the LbeIF4A antigen of Leishmania braziliensis.
  • the LbeBF4A antigen, or immunogenic portions of it can be used to induce protective immunity against leishmaniasis, specifically L. donovani. L. chagasi, L. infantum, L. major, L. braziliensis, L. panamensis, L. tropica and L. guyanensis. It can also be used diagnostically to detect Leishmania infection or to stimulate a cellular and/or humoral immune response or to stimulate the production of interleukin-12. This gene is expressed primarily in colon cancer and to a lesser extent in pituitary.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of cancers particularly of the colon.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the gastrointestinal system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 249 as residues: Glu-93 to Ala-98, Gin- 150 to Leu- 156, Leu-220 to Leu-231, Leu-268 to Arg-273, Val-324 to Pro-341, Arg-372 to Asn- 380, Ser-405 to Gly-410, Phe-426 to Ala-433, Glu-458 to Asp-470, Arg-506 to Ser- 547.
  • tissue distribution and homology to RNA helicase indicates that polynucleotides and polypeptides corresponding to this gene are useful for development of diagnostic tests for colon cancer.
  • the translation product of this contig has sequence homology to a cytoplasmic protein that binds specifically to JNK designated the JNK interacting protein- 1 or JIP-1 in mice.
  • JIP-1 caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression.
  • This gene is expressed primarily in brain including pituitary cerebellum frontal cortex, fetal brain and to a lesser extent in the kidney cortex.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of the central nervous system disorders including ischemia, epilepsy, Parkinson's disease, and schizophrenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • the standard gene expression level i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the translation product of this contig may suppress the effects of the JNK signaling pathway on cellular proliferation, including transformation by the Bcr-Abl oncogene.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 250 as residues: Pro-6 to Ser-26, Ala-30 to Asp- 41, Gly-55 to Ser-61, Gly-74 to Thr-80, Tyr-117 to Ala-123, Tyr-167 to Asp-172, Ala-212 to Cys-223, Pro- 239 to Tyr-244.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for enhanced survival and/or differentiation of neurons as a treatment for neurodegenerative disease.
  • the translation product of this gene shares sequence homology with a liver stage antigen from a protozoan parasite.
  • This gene is expressed primarily in fetal tissue and to a lesser extent in activated T-cells and other immune cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities and diseases of immune function.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to a protozoan antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/immune modulation of parasitic infections.
  • Preferred polypeptide encoded by this gene comprise the following polypeptide sequences:
  • This gene is expressed primarily in stromal and CD34 depleted bone marrow cells and to a lesser extent in tissues of embryonic origin.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of hematologic origin including cancers and immune dysfunction.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematapoietic and immune
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 252 as residues: Ser-28 to Gln-34.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a growth factor for hematopoietic stem cells or progenitor cells which may be useful in the treatment of chemotherapy patients suffering from neutropenia.
  • Preferred polypeptide fragments can be found in an alternative open reading frame. These preferred polypeptides comprise the amino acid sequence: MSSDNESDIEDEDLKLELRRLRDKHLKEIQDLQSRQKHEIESLYTKLGKVPPAVI IPPAAPLSGRRRRPTKSKGSKSSRSSSLGNKSPQLSGNLSGQSAASVLHPQQTL HPPGNIPESGQNQLLQPLKPSPSSDNLYSAFTSDGAISVPSLSAPGQGTSSTNTV GATVNSQAAQAQPPAMTSSRKGTFTDDLHKLVDNWARDAMNLSGRRGSKGH MNYEGPGMARKFSAPGQLCISMTSNLGGSAPISAASATSLGHFTKSMCPPQQY GFPATPFGAQWSGTGGPAPQPLGQFQPVGTASLQNFNISNLQKSISNPPGSNL RTT (SEQ ID NO:462); IQDLQSRQKHEIESLYTKLGKVPPAVIIPPAAPLSGRRRR PTKSKGSKSSRSSSLGNKSPQ
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver and CNS diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the liver and CNS
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 253 as residues: Gln-26 to Lys-34.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for liver diseases such as hepatocellular carcinomas and diseases of the CNS.
  • this gene shows sequence homology to two recently cloned genes, karyopherin beta 3 and Ran_GTP binding protein 5.
  • the Ran_GTP binding protein is related to impoitin-beta, the key mediator of nuclear localization signal (NLS)- dependent nuclear transport. Based on homology, it is likely that this gene may activity similar to the RAN_GTP binding protein.
  • Preferred polypeptide fragments comprise the amino acid sequence: VRVAAAESMXLLLECAXVRGPEYLTQMWHFMCDALIKA IGTEPDSDVLSEIMHSFAK (SEQ ID NO:467). Also preferred are polynucleotide fragments encoding these polypeptide fragments. This gene is expressed in thymus tissue.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for immune disorders.
  • This gene is expressed primarily in prostate and osteoclastoma tissues.
  • Preferred polypeptide fragments also comprise the amino acid sequence: ME-NNQNCHVIDLVRTV-v-ENGVEGLLIFG- -FLPESWLIGVRCSSEPP- ⁇ -ALLLIL
  • AHSQKRRLDGWSFIRHLRVHYCVSLTIHFS (SEQ ID NO:468). Also preferred are polynucleotide sequences encoding this polypeptide fragment.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, bone and prostate diseases, and cancers, particularly of the bone and prostate.
  • diseases and conditions which include, but are not limited to, bone and prostate diseases, and cancers, particularly of the bone and prostate.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the bone and prostate systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 255 as residues: Met-1 to Ser-11.
  • the tissue distribution indicates that polynucleotides and polypeptid
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample, especially for those susceptible to immune suppressant therapies and for diagnosis of diseases and conditions, which include, but are not limited to, immune suppressant disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 256 as residues: Ala-19 to Val-31, Arg- 38 to Gly-49, Ala-61 to Lys-66, Tyr-68 to Pro-78, Gly-116 to Ala- 121, Asp- 154 to Ser-162, Glu-173 to Gln-186, Phe-194 to Gly-203, Pro-207 to Val-212.
  • the tissue distribution and homology to FKBP-12 and -13 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for immune suppressant disorders.
  • This gene is expressed primarily in the brain and in the retina. This gene maps to chromosome 8, and therefore can be used in linkage analysis as a marker for chromosome 8.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and ocular associated disease states.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the disorders of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 257 as residues: Cys-34 to Asp-40.
  • tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma.
  • Expression in the brain indicates a role in the is useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • stathmin family This gene shows sequence homology to a newly identified class of proteins expressed in the nervous system, called stathmin family. (See Accession No. 2585991; see also Eur. J. Biochem. 248 (3), 794-806 (1997).)
  • stathmin family appears to be an ubiquitous phosphoprotein involved as a relay integrating various intracellular signaling pathways. These pathways affect cell proliferation and differentiation.
  • Preferred polypeptide fragments comprise the amino acid sequence: QDKHAEEVRKNKELKEEASR (SEQ ID NO:469); QQDLSPWAAPVGCPLXXASX TCHXLPLSGCLRRQSXSLPVVAXLCFWFSCPLASLFVPGQPCVTCPFPSLPFQD KHAEEVRKNKELKEEASR (SEQ ID NO:470). Also preferred are the polynucleotide fragments encoding these polypeptide fragments. This gene is expressed primarily in brain.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the polynucleotide sequence of this gene contains a domain similar to a Flt3 ligand peptide.
  • Preferred polypeptide fragments comprise the amino acid sequence: PTRCCTTQPCRSSARRPCWVPMVPSPEGREXQPTCPS (SEQ ID NO-471).
  • this gene may have activity as binding to Flt3 receptors, a process known to promote angiogenesis and/or lymphangiogenesis.
  • This gene is expressed in human tonsil, and to a lesser extent in teratocarcinoma, placenta, colon carcinoma, and fetal kidney.
  • polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the tonsil, as well as cancers, such as colon, reproductive, and kidney cancers.
  • diseases and conditions include, but are not limited to, diseases of the tonsil, as well as cancers, such as colon, reproductive, and kidney cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the tonsils, colon, reproductive organs, and kidneys
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 259 as residues: Pro-22 to Glu-33.
  • the tissue distribution in tonsil and several cancers and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the tonsil or colon, such as tonsillitis, inflammatory diseases involving nose and paranasal sinuses, especially during the infection of influenza, adenoviruses, parainfluenza, rhinoviruses.
  • the gene may also be useful in the diagnosis and treatment of neoplasms of nasopharynx or colon origins.
  • Preferred polypeptide fragments comprise the amino acid sequence:
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders, including cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a hormone with reproductive or other systemic functions; contraceptive development; male infertility of testicular causes, such as Kleinfelterfs syndrome, varicocele, orchitis; male sexual dysfunctions; testicular neoplasms; and inflammatory disorders such as epididymitis.
  • This gene is expressed primarily in apoptotic T-cell.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases relating to T cells, as well as cancer in general.
  • diseases and conditions which include, but are not limited to, diseases relating to T cells, as well as cancer in general.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the disorders of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for immune disorders. Moreover, since the gene was isolated from an apoptotic cell and based on the understanding of the relationship of apoptosis and cancer, it is likely that this gene may play a role in the genesis of cancer. FEATURES OF PROTEIN ENCODED BY GENE NO: 29
  • This gene is expressed primarily in human tonsils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, gastrointestinal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the gastrointestinal system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of gastrointestinal diseases.
  • polypeptide fragments comprise the amino acid sequence: GVFRPCVCGRPASLTCSPLDPEVGPYCDTPTMRTLFNLLWLALACSPVHTTLSK SDAKI ⁇ J-ASKTLLEKSQFSD--PVQDRGL ⁇ TDL--AESVVLEHRSYCSA--ARDRH FAGDVLGYVTPWNSHGYDVTKVFGSKFTQISPVWLQLKRRGREMFEVTGLHD VDQGWMl- AVR-KHAKGLffl RLLFEDWTYDDFRNVLDSEDEIEELSKTVVQVA KNQH-roGFVVEVWNQLLSQK-RVGLIHMLTHL- ⁇ EALHQAl-LLALLVIPPAITPGT DQLGMFTHKEFEQLAPVLDGFSLMTYDYSTAHQPGPNAPLSWVRACVQVLDP KXKW
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 263 as residues: Leu-21 to Ala-30, Ser-38 to Asp-47, Pro-87 to Asp-94, Leu-197 to Thr-204, Pro-256 to Ser-262, Thr-277 to Arg-282, Thr-293 to Trp-303.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders and gastrointestinal diseases.
  • This gene is expressed in human embryo tissue and to a lesser extent in human epithelioid sarcoma and other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development disorders and epithelial cell cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the embryonic and epithelial cell systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 264 as residues: Lys-34 to Gly-40.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental disorders and epithelial cancer.
  • This gene is expressed primarily in resting T cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory and general immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders of immune system.
  • This gene is believed to reside on chromosome 1. Accordingly, polynucleotides derived from this gene are useful in linkage analysis as chromosome 1 markers.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate-related disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissues or cells particularly of the urinary system and nervous system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution indicates that the protein products of this gene are useful for the diagnosis and treatment of disorders of the urinary and nervous systems.
  • This gene shares sequence homology with R05G6.4 gene product. (See Accession No. gill 326338.) This gene also shares sequence homology with the cyclophilin-like protein CyP-60. (See Accession No. 1199598, see also Biochem. J.
  • Preferred polypeptide fragments comprise the amino acid sequence: AVYTYHEKKKDTAASGYGTQNIRLSRDAVK-DFDCCCLSLQPCHDPVVTPDGYL YEREAJLEYILHQ----K ⁇ --ARQM---AYEKQRGTRREEQKELQRAASQDHVRGFLEKE SAIVSRP LNPFTAKALSGTSPDDVQPGPSVGPPSKDKDKVLPSFWIPSLTPEAK ATKLEKPSRTVTCPMSGKPLRMSDLTPVHFTPLDSSVDRVGLITRSERYVCAVT RDSLSNATPCAVLRPSGAVVTLECVEKLIRKDMVDPVTGDKLTDRDIIVLQRGT (SEQ ID NO:484); YLYEREAILEYILHQKKEIARQMKAYEKQRGTRREEQKELQ RAASQDHVRGFLE (SEQ ID NO:485); and FTAKALSGTSPDDV
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders and in particular testicular cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system.
  • Expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders of the male reproductive system and in particular of testicular cancer.
  • the translation product of this gene shares sequence homology with Lpe5p of Saccharomyces cerevisiae which is thought to be important in the metabolism of phospholipids.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the metabolic and nervous systems expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 268 as residues: Pro-14 to Leu-20, Lys-28 to Asn-38, Arg-109 to Arg-114, Lys- 119 to Asn-124, Glu-152 to Leu- 157, Pro- 172 to Val-180.
  • Preferred polypeptide fragments comprise the amino acid sequence: MDTSENRPENDVPEPPMPIADQVSNDDRPEGSVEDEEKKESSLPKSFKRKISVV SATKGVPAGNSDTEGGQPGRKRRWGASTATTQKKPSISITTESLKSLIPDIKPL AGQEAVVDLHADDSRISEDETERNGDDGTHDKGLKICRTVTQVVPAEGQENGQ REEEEEEKEPEAEPPVPPQVSVEVALPPPAEHEVKKVTLGDTLTRRSISQQKSGV SITIDDPVRTAQVPSPPRGI- ⁇ SNIVHISNLVl ⁇ l- LGQLKELLGRTGTLVEEAFWI DKIKSHCFVTYSTVEEAVATRTALHGVKWPQSNPKFLCADYAEQDELDYHRGL LVDRPSETKTEEQGIPRPLHPPPPV
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the male reproductive system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of male reproductive disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory diseases and reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the amygdala
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory diseases and reproductive disorders.
  • opsonin protein P35 fragment This gene shares sequence homology with human opsonin protein P35 fragment. (See Accession No. R94181.)
  • the opsonin protein activates the phagocytosis of pathogenic microbes by phagocytic cells.
  • Preferred polypeptide fragments comprise the amino acid sequence: GCDSCPPHLPREAFAQDTQAEGECSSRAERADMCPDAP PSQEVPEGPGAAP (SEQ ID NO:489). Also preferred are polynucleotide fragments encoding these polypeptide fragments. This gene is expressed in immune-related tissues such as thymus, macrophage,
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders and infectious disease.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system and infectious disease
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder., relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 271 as residues: Lys-9 to Arg-14, Met-38 to Asp-51.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders, as well as the treatment and/or diagnosis of infectious disease.
  • Preferred polypeptide fragments comprise the amino acid sequence: PQLPSCGRPW PGTASVFQSHTQGPREDPDPCRAQGSAGTHCPISLSPPRQ (SEQ ID NO:490). Also preferred are the polynucleotide sequences encoding these polypeptide sequences. This gene is expressed primarily in the brain and to a lesser extent in the kidney and thymus
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain, kidney, and immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the brain, kidney, and immune disorders
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to alpha-2 type I collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tissue repair, and brain, kidney, immune disorders.
  • polypeptide fragments comprise the amino acid sequence: PGFRGPSGSLGCSFFPRSLGRVLPPGCQRPGAHAD SSPPPTP (SEQ ID NO:491). Also preferred are polynucleotides encoding this polypeptide fragment.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumor metastasis and tissue repair.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the tumor metastasis and tissue repair
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 273 as residues: Asn-2 to His-11.
  • tissue distribution and homology to mini-collegen gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of tumor metastasis and tissue repair.
  • Preferred polypeptide fragments comprise the amino acid sequence: EDLKKPDPASLRAASCGEGKKRKACKNCTCGLAEELEKEK SREQMSSQPKSACGNCYLGDAFRCASCPYLGMPAFKPGEKVLLS (SEQ ID NO:492); EDLKKPDPASLRAASCGEGKKRKACKNCTCGLAEELEKEK SREQMSSQPKSACGNCYLGDAFRCASCPYLGMPAFKPGEKVLLSDSNLHD (SEQ ID NO:493); CGNCYLGDAFRCASCPYLGMPAFKPGEKVLLSDS
  • polynucleotide fragments encoding these polypeptide fragments are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain, testes and breast disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) particularly of the brain, testes and breast disorders
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 274 as residues: Pro-7 to Val-15.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of brain, testes and breast, and other related disorders.
  • PROTEIN ENCODED BY GENE NO: 42 This gene is expressed primarily in the infant brain, human cerebellum, and to a lesser extent in medulloblastoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain related disorders and medulloblastoma and other brain cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the brain related disorders and brain cancers, including medulloblastoma
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of human brain related disorders, brain cancers, and medulloblastoma.
  • Preferred polypeptide fragments comprise the amino acid sequence: ESSGQARTLADPGPGWPRQQGMCFGSLT
  • GLSTTPHGFLTVSAEADPP-LffiSLSQMLSMGFSDEGGWLTRLLQTKNYDIGAAL DTIQYSKH (SEQ ID NO:498).
  • polynucleotide fragments encoding this polypeptide fragment are also preferred. It is likely that this gene is a new member of a family of phosphotyrosine-independent ligands for the lck SH2 domains. This gene is expressed primarily in the placenta and to a lesser extent in endothelial cells and neutrophil.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive, cardiovascular, immune, and infectious diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) particularly of the cardiovascular, reproductive, and immune system, and infectious diseases
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to a phosphotyrosine-independent ligand for the lck SH2 domain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cardiovascular, reproductive, and immune system diseases, as well as infectious diseases.
  • This gene is expressed primarily in the fetal brain, cerebellum and to a lesser extent in the placenta.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal cell related disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neuronal cell related disorders
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 277 as residues: Thr-20 to Gly-28.
  • tissue distribution and homology to proline-rich protein genes indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal cell related disorders.
  • the translation product of this gene shares sequence homology with precerebellin of human, which is thought to be important in synaptic physiology. (See Accession No. gil 180251.) It has been observed that cerebellin-like immunoreactivity is associated with Purkinje cell postsynaptic structures. Thus, it is likely that this gene also have synaptic activity.
  • Preferred polypeptide fragments comprise the amino acid sequence: QEGSEPVLLEGECLVVCEPGRAAAGGPGGAALGEAPPGRVAFXAV RSHHHEPAGETGNGTSGAIYFDQVLVNEGGGFDRASGSFVAPVRGVYSFRFH VVKVYNRQTVQVSLMLNTWPVISAFANDPDVTREAATSSVLLPLDPGDRVSLR LRRGXSTGW (SEQ ID NO:499). Also preferred are polynucleotide fragments encoding these polypeptide fragments.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal cell signal transduction and synaptic physiology.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissues or cells particularly of the neuronal cell signal transduction and synaptic physiology expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to gene or gene family indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal cell related disorders.
  • This gene is expressed in fetal liver and spleen, and to a lesser extent in bone marrow, umbilical vein, and T cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the immune system, particularly hematopoiesis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematopoiesis and immune disorders
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 279 as residues: Asp-30 to Glu-57.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopieotic and immune disorders.
  • the translation product of this gene shares sequence homology with a 12 kD nucleic acid binding protein of Feline calcivirus which is thought to be important in viral replication. (See Accession No. 59264) This gene is expressed primarily in human cardiomyopathy and to a lesser extent in T helper cells, fetal brain and synovial sarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiomyopathy as well as viral infection.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the cardiovascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 280 as residues: Trp-20 to Cys-26.
  • tissue distribution in cardiomyopathy and homology to viral 12 kD nucleic acid binding protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of cardiomyopathy, including those caused by ischemic, hypertensive, congenital, valvular, or pericardial abnormalities.
  • the gene expression pattern may be the consequence or the cause for these conditions.
  • the translation product of this gene shares sequence homology with tumor necrosis factor related gene product which is thought to be important in tumor necrosis, bacterial and viral infection, immune diseases and immunoreactions.
  • This gene is expressed primarily in colon and to a lesser extent in ovarian and breast cancers.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of colon, ovary or breast origins.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the colon, ovary and breast
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to Tumor necrosis factors indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of cancers of colon, ovary and breast origins, because TNF family members are known to be involved in the tumor development.
  • polypeptide fragments comprise the following amino acid sequence: PRSRPALRPGRQRPPSHSATSGVLRPRKKPDP (SEQ ID NO:500). Also preferred are polynucleotide fragments encoding these polypeptide fragments.
  • this gene maps to chromosome 22ql 1.2-qter, and therefore, can be used as a marker in linkage analysis for chromosome 22.
  • This gene is expressed primarily in corpus colosum.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors, especially of corpus colosum, as well as metastatic lesions.
  • diseases and conditions which include, but are not limited to, tumors, especially of corpus colosum, as well as metastatic lesions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the corpus colosum and other solid tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to mucins indicates that polynucleotides and polypeptides corresponding to this gene are useful for serum tumor markers or immunotherapy targets because tumor cells have greatly elevated level of mucin expression and shed the molecules into the epithelial tissues.
  • This gene is expressed primarily in CD34 depleted buffy coat cord blood and primary dendritic cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic disorders and immunological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematopoietic and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in CD34 depleted buffy coat cord blood and primary dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hematopoietic and immune disorders.
  • Secreted or cell surface proteins in the above tissue distribution often are involved in cell activation (e.g. cytokines) or molecules involved in cell surface activation.
  • polypeptide fragment comprise the following amino acid sequences: MTLITPSXKLTFXKGNKSWSSRACSSTLVDP (SEQ ID NO:501). Also preferred are polynucleotide fragments encoding these polypeptide fragments. This gene is expressed primarily in CD34 positive cells and neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, retroviral infection, such as AIDS, and other immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 284 as residues: Gln-51 to Trp-62.
  • tissue distribution and homology to interferon induced gene 1-8 indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of retroviral infection including HIV.
  • the factor may be involved in viral stability or viral entry into the cells. Alternatively, the virus/factor complex may elicit the cellular immune reaction.
  • polypeptide fragments comprise the following amino acid sequence: GHPSPALSIAPSDGSQLPCDEVPYGEAHVTRYCKKPLTNS HLETEAQSSSL (SEQ ID NO:502). Also preferred are polynucleotide fragments encoding these polypeptide fragments.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, Hodgkin's lymphoma and other immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 285 as residues: Pro-27 to Thr-32.
  • the tissue distribution in Hodgkin's lymphoma and the sequence homology indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of Hodgkin's lymphoma, since the elevated expression and secretion by the tumor mass may be indicative of tumors of this type.
  • the gene product may be used as a target in the immunotherapy of the cancer.Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • This gene has extensive homology to cDNA for Homo sapiens mRNA for the ISLR gene(See Accession No. AB003184).
  • This protein is considered to be a new member of the Ig superfamily and contains a leucine-rich repeat (LRR) with conserved flanking sequences and a C2-type immunoglobulin (Ig)-like domain. These domains are important for protein-protein interaction or cell adhesion, and therefore it is possible that the novel protein ISLR may also interact with other proteins or cells.
  • LRR leucine-rich repeat
  • Ig immunoglobulin
  • This gene is expressed in a number of tissues including human retina, heart, skeletal muscle, prostate, ovary, small intestine, thyroid, adrenal cortex, testis, stomach, spinal cord, fetal lung and fetal kidney tissues, colon, tonsil and stomach cancer, and to a lesser extent in endometrial stromal cells treated with estradiol, breast tissue, synovium, lymphoma, and number of other tumors.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of colon, ovary and breast origins.
  • diseases and conditions which include, but are not limited to, tumors of colon, ovary and breast origins.
  • protein may play a vital role in the development of cancer in other tissues as well, not just those mentioned above.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • this gene maps to chromosome 15q23- q24, and therefore, can be used as a marker in linkage analysis for chromosome 15.
  • tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • P06795 P06795
  • Preferred polynucleotide fragments comprise the following sequence: GCTTCGTGTCCAACCCTCTTGCCCTTCGCCTGTGTGCCTGGAGCCAGTCCCA CCACGCTCGCGTTTCCTCCTGTAGTGCTCACAGGTCCCAGCACCGATGGCA TTCCCTTTGCCCTGAGTCTGCAGCGGGTCCCTTTTGTGCTTCCTTCCCCTCA GGTAGCCTCTCTCCCCCTGGGCCACTCCCGGGGGTGAGGGGGTTACCCCTT CCCAGTGTTTTTTATTCCTGTGGGGCTCACCCCAAAGTATTAAAAGTAGCTTT GTAA (SEQ ID NO:503). Also preferred are polypeptide fragments encoded by these polynucleotide fragments.
  • This gene is expressed primarily in lung, esophagus, leukemia (Jurkat cells) and breast cancers and to a lesser extent in macrophages treated with GM-CSF fetal tissues and wide range of tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer of wide range of origins.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the solid tumors, lung and leukemia
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • protein as well mutants thereof may also be beneficial as a target for gene therapy, particularly for the chronic patient.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 287 as residues: Met-1 to Lys-16.
  • tissue distribution in wide range of cancers and fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of cells in active proliferation, such as cancers.
  • the gene products may be used for cancer markers or immunotherapy target.
  • This gene maps to the X chromosome. This gene is expressed primarily in the brain and to a lesser extent in the developing embryo.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disease states and developmental disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • this gene For a number of disorders, including sex-linked disorders, of the above tissues or cells, particularly of the neurological, developmental systems, and cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • this gene maps to the X chromosome, and therefore, may be used as a marker in linkage analysis for this chromosome.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Klinefelter's, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.
  • polynucleotide fragments comprise the following sequence: TGGCTCACTGTCTTACAATCACTGCTGTGGAATCATGA TACCACTTTTAGCTCTTTGCATCTTCCTTCAGTGTATTTTTGTTTTTCAAGAGG AAGTAG ATTTTA ACTGGAC AACTTTG AGTACTG AC ATCATTG AT AAAT AAACT GGCTTGTGGTTTCAA (SEQ ID NO: 506). Also preferred are polypeptide fragments encoded by these polynucleotide fragments.
  • polypeptide fragments comprise the amino acid sequence: LDELMAHLTEMQAKVAVRAD AGKKHLPDKQDHKASLDSMLGGLEQELQDLGIATVPKGHCASCQKPIAGKVI HALGQS WHPEHFVCTHCKEEIGSSPFFERSGLXYCPNDYHQLFSPRCA YCAAP ILDKVLTAMNQTWHPEHFFCSHCGEVFGAEGFHEKDKKPYCRKDFLAMFSPK CGGCNRPVLENYLSAMDTVWHPECFVCGDCFTSFSTGSFFELDGRPFCELHYH HRRGTLCHGCGQPITGRCISAMGYKFHPEHFVCAFCLTQLSKGIFREQNDKTY CQPCFNKLF (SEQ ID NO:507); KASLDSMLGGLEQELQDLGIATVPKGHC ASCQKPIAGKVIHAL (SEQ ID NO:508); CPNDYHQLFSPRCAYCAAPILDKVL TAMNQTWHPEHFFCSHC
  • This gene is expressed primarily in brain, and to a lesser extent in the developing embryo.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disease states and developmental abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • this gene For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Moreover, since this gene shares homology with a gene that maps to chromosome 11, (See Accession No.T87404), gene as well as its translated product may be used for linkage analysis on chromosome 11.
  • tissue distribution and homology to paxillin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and or detection of disease states associated with abnormal signal transduction in brain and/or the developing embryo.
  • This gene is expressed primarily in fetal spleen, brain, and to a lesser extent in six week old embryo.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders, neurological disorders, and developmental abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 290 as residues: Arg-28 to Gly-34.
  • this gene in fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/detection of immune disorders such as arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • the expression of this gene in the early embryo indicates a key role in embryo development and hence the gene or gene product could be used in the treatment and or detection of embryonic development defects. This would include treatment or detection of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder and also in the treatment and or detection of embryonic development defects.
  • polypeptide fragments comprise the following:
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological conditions and pulmonary disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the nervous ⁇ pulmonary, and endocrine systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or cells e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 291 as residues: Asn-9 to Leu- 14.
  • this gene in fetal lung would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung; that it may also be involved in predisposition to certain pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis; and thus the gen or the gene protein encoded by the gene could be used in the detection and/or treatment of these pulmonary disorders.
  • This gene is expressed primarily in the developing embryo.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the developmental system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • the expression of this gene primarily in the embryo, indicates the gene plays a key role in embryo development and that the gene or the protein encoded by the gene could be used in the treatment and or detection of developmental defects in the embryo or in infants.
  • This gene displays homology to nestin, an intermediate filament protein, the expression of which correlates with the proliferation of Central Nervous System progenitor cells and that is useful in the identification of brain tumors.
  • This gene maps to chromosome 1 , and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. AA527348).
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, renal disorders and neurodegenerative conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the excretory and nervous systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 293 as residues: Thr-128 to Asn-135.
  • tissue distribution and homology to nestin indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and/or treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • its abundance in kidney indicates that it is useful in the treatment and detection of acute renal failure and other disease states associated with the kidney.
  • Preferred polypeptide fragments comprise the following amino acid sequence:
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders and hematopoeitic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neurological and hematopoeitic systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 294 as residues: Lys-13 to Leu-21.
  • tissue distribution of this gene suggest that it may be useful in the detection and/or treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder, while its expression in hematopoietic cell types indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma and immunodeficiency diseases.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematological and immunological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune and hematopoetic systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or spleen indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, leukemia, asthma and immunodeficiency diseases.
  • ALTRIPPGDWVINVTAVSFAGKTTARFFHSSPPSLGDQARTDPGHQRRD SEQ ID NO:520
  • polynucleotide fragments encoding these polypeptide fragments This gene maps to chromosome 9, and therefore, may be used as a marker in linkage analysis for chromosome 9 (See Accession No. AA004342).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic and immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution of this gene in fetal liver-spleen indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, leukemia, asthma, and immunodeficiency diseases.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disease states.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the neurological systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntintons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • polypeptide fragments comprise the following amino acid sequence: LQEVNITLPENSVWYERYKFDIP
  • VFHL (SEQ ID NO:521). Also preferred are polynucleotide fragments encoding these polypeptide fragments. (See Accession No. 1332638)
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver disorders and cancers (e.g. hepatoblastoma).
  • diseases and conditions which include, but are not limited to, liver disorders and cancers (e.g. hepatoblastoma).
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hepatic system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 298 as residues: Asn-59 to Glu-64.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells).
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would- healing models and/or tissue trauma.
  • polynucleotide fragments comprise the following sequence: TAGCATGTAGCCAGTCGAATAACNTATAAGGACAAAGTGGAGTC CACGCGTGCGGCCGTCTAGACTAGTGGATCCCCCGGCTGCAGGATTCGGC ACGAG (SEQ ID NO:523). Also preferred are polypeptide fragments encoded by these polynucleotide fragments (See Accession No.T94535). Additionally, this gene shares homology with an interferon-gamma receptor.
  • Preferred polypeptide fragments also comprise the following amino acid sequence: MQGSGSQFRACLLCLCFSCPC SPGGPRWNSRQGGRRFPKTCRAISQNLVFKYKTFCPVRYMQPHRSSLCLHFTS YVFILSTWGSLRTYSTDLKKKKKNSRGGPVPIRPKS (SEQ ID NO:522);
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological disorders and conditions (immunodeficiencies, cancer, leukemia, hematopoeisis).
  • diseases and conditions which include, but are not limited to, immunological disorders and conditions (immunodeficiencies, cancer, leukemia, hematopoeisis).
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and digestive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 299 as residues: Thr-41 to Gly-52.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of immune disorders including: leukemias, lymphomas, auto-immune disorders, immuno- supressive (transplantation) and immunodeficiencies (e.g. AIDS), inflammation and hematopoeitic disorders.
  • immune disorders including: leukemias, lymphomas, auto-immune disorders, immuno- supressive (transplantation) and immunodeficiencies (e.g. AIDS), inflammation and hematopoeitic disorders.
  • the expression of this gene in gall bladder would suggest a possible role for this gene product in digestive disorders, particularly of the pancreas.
  • This gene maps to chromosome 11, and therefore, may be used as a marker in linkage analysis for chromosome 11 (See Accession No. AA011622).
  • This gene is expressed primarily in a variety of fetal and developmental tissues (e.g. fetal spleen, infant brain).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental, immune or neurological abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the developing immune and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 300 as residues: Ser-38 to Ser-43.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for developmental abnormalities or fetal deficiencies.
  • the detection in infant brain would suggest a role in neurological disorders (both developmental and neurodegenerative conditions of the brain and nervous system, behavioral disorders, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia).
  • the detection in spleen would similarly suggest a role in detection and treatment of immunologically mediated disorders (e.g. immunodeficiency, inflammation, cancer, wound healing, tissue repair, hematopoeisis).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological deficiencies, including AIDSand cardiovascular disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, autoimmune disorders, immunodeficiencies (e.g.
  • fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cadiovascular disorders (e.g. heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis).
  • cadiovascular disorders e.g. heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis.
  • Preferred polypeptide fragments comprise the following amino acid sequence: MPRKTSKCRQLLCSGASRNADTAARQSTCSSHRPPGKIPSLGPRRXPGCXSVP SSRGEQSTGSPAAPRCGRRDAHRGLPGGAAMTPGDTWASFNPRAGHSKSQGE GQESSGASRQDRHPVSHWVERQREAWGAPRSSSAGGVKVAATTEREPEFKIK TGKA (SEQ ID NO:527); CSGASRNADTAARQSTCSSHRPPGKIPSLGPRRXPG CXSVPSSRGEQSTGSPAAPRCGRRDAHRGLPGGAAMTPGDTWASFNPRAGHS (SEQ ID NO:528); QGEGQESSGASRQDRHPVSHWVERQREAWGAPRSSSAGG VKVAATTEREPEFKIKTGKA (SEQ ID NO:529) (See Accession No.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the cardiovascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 302 as residues: Pro-32 to Ser-39.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cadiovascular disorders (e.g. heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis).
  • cadiovascular disorders e.g. heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis.
  • polypeptide fragments comprise the following amino acid sequence:
  • This gene is expressed primarily in placenta and to a lesser extent in the fetal heart and a variety of other tissues and cell types.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities, fetal deficiencies, and particularly of the cardiovascular system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of developmental abnormalities or fetal deficiencies, ovarian and other endometrial cancers, reproductive dysfunction, cardiovascular disorders, and pre-natal disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver disorders (including hepatoblastomas) and reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hepatic and reproductive systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells).
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • the expression in testes and breast indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of endocrine and reproductive disorders (e.g. sperm maturation, milk production, testicular and breast cancers).
  • This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. W93595).
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular and neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell ty ⁇ e(s).
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of restenosis, atherosclerosis, stroke, angina, thrombosis, wound healing and other conditions of heart disease.
  • polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of developmental, degenerative and behavioral conditions of the brain and nervous system (e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders).
  • developmental, degenerative and behavioral conditions of the brain and nervous system e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders.
  • polypeptide fragments comprise the following amino acid sequence:
  • polynucleotide fragments encoding these polypeptide fragments See Accession No.R65208 . This gene maps to chromosome 7, and therefore, may be used as a marker in linkage analysis for chromosome 7 (See Accession No. D52585).
  • This gene is expressed primarily in the brain (infant brain, adult brain, pituitary, cerebellum, hippocampus, schizophrenic hypothalmus, amygdala).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system.
  • diseases and conditions which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 306 as residues: Thr-25 to Lys-36, Lys- 55 to Ser-63.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of developmental, degenerative and behavioral conditions of the brain and nervous system (e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders).
  • developmental, degenerative and behavioral conditions of the brain and nervous system e.g. schizophrenia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior and sleep disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the CNS particularly schizophrenia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissues or cells particularly of the CNS
  • schizophrenia expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 307 as residues: Gly-38 to Ala-44.
  • tissue distribution indicates that the protein products of this gene are useful for the study, diagnosis and treatment of schizophrenia and other disorders involving the CNS.
  • Preferred polypeptides of the invention comprise the following amino acid sequence encoded by this gene:
  • polynucleotides encoding such polypeptides are also provided. This gene is expressed primarily in endometrial tumor and to a lesser extent in amniotic cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive and immune disorders particularly cancers of those systems.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 308 as residues: Ser-3 to Arg-9. The tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune and reproductive disorders particularly cancers of those systems.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, renal disorders such as renal cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the kidney expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 309 as residues: Gly-38 to Gly-45, Gly-47 to Gly-52, Pro-92 to Lys-110
  • tissue distribution indicates that the protein products of this gene are useful for study, treatment and diagnosis of renal diseases such as cancer of the kidney.
  • This gene is expressed primarily in kidney medulla.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, metabolic and renal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the metabolic and renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for study, treatment and diagnosis of metabolic and renal diseases and disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, arthritis and atherosclerosis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution indicates that the protein products of this gene are useful for study, diagnosis and treatment of arthritic and other inflammatory diseases as well as cardiovascular diseases.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for the study and treatment of immune diseases such as inflammatory conditions.
  • T-cells TNF induced epithelial and endothelial cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infectious and immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune and vascular systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 313 as residues: Met-1 to Trp-6.
  • tissue distribution indicates that the protein products of this gene are useful for study and treatment of infectious diseases, immune and vascular disorders.
  • This gene is expressed in activated neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and other immune conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory and other immune conditions.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 315 as residues: Ala-83 to Thr-91.
  • the tissue distribution indicates that the protein products of this gene are useful for study and treatment of immune disorders.
  • This gene is expressed in human neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune and inflammatory system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the inflammatory and immune systems.
  • This gene is expressed in human neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the inflammatory and immune systems.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the inflammatory and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the immune and inflammatory systems.
  • This gene is expressed in activated neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which inelude, but are not limited to, inflammation and immune system diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system and inflammatory system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of diseases of the inflammatory and immune systems.
  • This gene is expressed in activated neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and immune system disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the inflammatory and immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 319 as residues: Met-1 to Gly-6, Gly-32 to Pro-43, Leu-55 to Gln-60.
  • tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of disorders of the immune and inflammatory system.
  • polypeptides of the invention comprise the sequence:
  • VQYEEVAEKDDLMGVEDTAKKGFXSKPSRSRNTIFTLGTRGSVISPTELEAPILV PHTAQR (SEQ ID NO: 542); EQRYPFEALFRSQHYXLLDNSCREYLFICEFFVVS GPXAHDLFHAVMGRTLSMTL- LDSYLA-DCYDAIAVFLCIHIVLRFRNIAAKRD VPALDRYW (SEQ ID NO:543),GGLDTRPHYITRRYAEFSSALVSINQ (SEQ ID NO:544); SRKEQLVFLINNYDMMLGVL (SEQ ID NO: 545) and/or ALLKYRFFY
  • KSSVESLSQDVMRSFTNFRNGTS SEQ ID NO:546
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • the translation product of this gene shares sequence homology with suppressor of actin mutation which is thought to be important in mutation suppression. This gene is expressed primarily in fetal liver and to a lesser extent in a variety of other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver and mutations.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the liver or cancer
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 320 as residues: Val-53 to Arg-60, Thr-88 to Thr-94, Ala- 142 to Ser-150, Gly-188 to Glu-196, Gly- 208 to Ser-214, Thr-227 to Gly-232, Lys-279 to Phe-285.
  • the tissue distribution and homology to suppressor of actin mutation suggest that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and of liver disorder or cancer.
  • polypeptides of the invention comprise the sequence:
  • VSEPAKVSECCRFILNLL (SEQ ID NO:550); and/or YEGKEFDYVFSIDVNEGGPS Y--LPYNTSDDPWLTAYNFLQKNDLNPMFLDQVA--PIIDNTKGQMLGLGNPSFS DPFTGGGRYVPGSSGSSNTLPTADPFTGAGRYVPGSASMGTTMAGVDPFTGN SAYRSAASKTMNIYFPKKEAVTFUQANPTQI GKLKELNGTAPEEKKLTEDDLI LLE- ⁇ LSLICNSSSE- ⁇ TVQQLQl-LWKAINCPEDIVFPALDILRLSIKHPSVNENFC NEKEGAQFSSHLINLLNPKGKPANQLLALRTFCNCFVGQAGQKLMMSQRESL MSHAffiLKSGSNKNIHIA-LATLALNYSVCFHKDHNIEGKAQCLSLISTILEVVQD LEATFRLLVALGTLISDDSNAVQLAKSLGVDSQIKKYSSVSEPA
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. These polypeptides share significant homology with phospholipase A2 activating protein which is thought to be important in signal transduction (see, e.g., Wang et al., Gene 161(2):237-241 (1995)).
  • This gene is expressed primarily in endothelial cells, to a less extent in placenta, endometrial stromal cells, osteosarcoma, testis tumor, muscle, and infant brain that are likely to be rich in blood vessles.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in vascular system, aberrent angiogenesis, tumor angiogenesis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the vascular system or tumors
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution of this gene in endothelial cells and several potential highly vascularized tissues and its homology to phospholipase A2 activating protein suggest that this gene may be involved in transducing signals for endothelial cells in angiogenesis or vasculogenesis .
  • polypeptides of the invention comprise the sequence: YPNQDGD-D-.RDQVL--EHIQI-LSKVVTANHRALQIPEVYLI--EAPWPSAQSEIRTIS AYKTPRDKVQC--LRMCSTI-MNLLSL- NEDSVPGADDFVPVLVFVLIKANPPCLL STVQYISSFYASCLSGEESYWWMQFTAAVE (SEQ ID NO:552); YPNQDGDILR DQVLHEHIQRLSKVVTANHRALQIPEVYLREAPWPSAQSEIRTISAYKTPRDKVQ CILRMCSTIMNLLSLANEDSVPGADDFVPVLVFVLIKANPPCLLSTVQYISSFYA SCLSGEESYWWMQFTAAVEFIKTI (SEQ ID NO:553); YPNQDGD--LRDQVL (SEQ ID NO:554); EAPWPSAQSEI (SEQ ID NO:555);
  • This gene is expressed primarily in T cells and melanocytes and to a lesser extent in a variety of other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, dysfunction and disorders involving T cells and melanocytes.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to ras inhibitor indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating signal transduction; diagnosis and treatment of disorders involving T cells and melanocytes.
  • polypeptides of the invention can be used in linkage analysis as a marker for chromosome 9.
  • the translation product of this gene shares sequence homology with neuronal olfactomedin-related ER localized protein which is thought to be important in influence the maintenance, growth, or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons.
  • polypeptides of the invention comprise the sequence:
  • SARASTQPPAGQHPGPC SEQ ID NO:561; MPGRWRWQRDMHPARKLLSLL FLILMGTELTQD (SEQ ID NO:562); SAAPDSLLRSSKGSTRGSL (SEQ ID NO:563); AAIVIWRGKSESRIAKTPGI (SEQ ID NO:564); FRGGGTLVLPPTHT PEWLIL (SEQ ID NO:567); PLGITLPLGAPETGGGD (SEQ ID NO:565); and/or CAAETWKGSQRAGQLCALLA (SEQ ID NO:566). This gene is expressed in pineal gland.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and endocrinological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neurological or endocrine systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 323 as residues: Leu-20 to Ala-26, Arg-32 to Arg-39, Thr-104 to Gly-112.
  • tissue distribution and homology to olfactomedin-related protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for maintenance, growth, or differentiation of neuron cells in pineal gland, therefore, may be useful for diagnosis and treatment of neurological disorders in pineal gland.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate disease and T cell dysfunction.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the prostate cancer
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for detect abnormal activity in prostate and T cells or probably treatment of this abnormality.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in prostate or vascular system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the prosate or vascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating function of prostate or highly vascularized tissues, e.g. placenta.
  • This gene is expressed primarily in embryos and fetal tissues stage human and to a lesser extent in a wide variety of other proliferative tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders in embryonic development and cell proliferation.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the embryonic tissues and proliferative cells
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of abnormalities in developing and proliferative cells and organs.
  • the translation product of this gene shares sequence homology with transformation related protein which is thought to be important in transformation.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer or dysfunction of reproductive tissues.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproduction system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 327 as residues: Ser-50 to Pro-61.
  • tissue distribution and homology to transformation related protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of conditions caused by transformation, i.e. tumorigenesis in reproductive organs, e.g. breast, placenta, and ovary.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumorigenesis, abnormal angiogenesis, and/or neurological disorders.
  • diseases and conditions which include, but are not limited to, tumorigenesis, abnormal angiogenesis, and/or neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the tumor tissues or vascular tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 328 as residues: Arg-46 to Trp-54, Pro- 60 to Ile-69, Asn-116 to Ala- 122, Arg-147 to Lys-153, Ser-158 to Glu-170, Ile-399 to Ser-405, Pro-486 to Met-499, Pro-502 to Asp-508.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for a range of disease states including treatment of tumor or vascular disorders and the treatment of neurological disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • neurological disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • This gene maps to chromosome 7 and therefore polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 7.
  • the translation product of this gene is homologous to the Clostridium perfringens enterotoxin (CPE) receptor gene product and shares sequence homology with a human ORE specific to prostate and a glycoprotein specific to oligodendrocytes both of which are tissue specific proteins.
  • CPE Clostridium perfringens enterotoxin
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pancreatic disorder, ulcerative colitis, tumors and food poisoning.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the digestive system or tumorigenic system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 329 as residues: Gly-147 to Met- 152, Cys-177 to Lys-188.
  • tissue distribution and homology to prostate and oligodendrocyte-specif ⁇ c protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for marker of diagnosis or treatment of disorder in pancreas, ulcerative colitis, and tumors.
  • identity to the human receptor for Clostridium perfringenes entertoxin indicates that the soluble portion of this receptor could be used in the treatment of food poisoning associated with Clostridia perfringens by blocking the activity of perfringens enterotoxin.
  • the translation product of this gene shares sequence homology with ATPase which is thought to be important in metabolism. This gene is expressed primarily in testes and several hematopoietic cells and to a lesser extent in other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemia and hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematopoietic system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 330 as residues: Leu-37 to Ala-42.
  • tissue distribution and homology to ATPase indicates that polynucleotides and polypeptides corresponding to this gene are useful for marker of diagnosis and treatment of leukemia and other hematopoietic disorders.
  • polypeptides of the invention comprise the sequence: MRSARPSLGCLPSWAFSQALNI (SEQ ID NO:568); LLGLKGLAPAEISAVCE KGNFN (SEQ ID NO:569); VAHGLAWSYYIGYLRLILPELQARIR (SEQ ID NO:570); TYNQHYNNLLRGAVSQRC (SEQ ID NO:571); ILLPLDCGVPDNLSM ADPNIRFLDKLPQQTGDRAGIKDRVYSN (SEQ ID NO:572); SIYELLENGQRAGT CVLEYATPLQTLFAMSQYSQAGFSGEDRLEQ (SEQ ID NO:573); AKLFCRTLE DILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAV PSTSTMSQEPELLISGMEKPLPLRTDFS (SEQ ID NO:574); and/or LLGLKGLA PAEISAVCEKGNFNVAHGLAWSYYIG
  • polypeptides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in prostate BPH and to a lesser extent in bone marrow. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, benign prostatic hypertrophy or prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male urinary system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 331 as residues: Ue-60 to Asn-69, Leu-106 to Asp-112, Glu-130 to Gly-136, Phe- 160 to Glu-167, Pro-184 to Cys-190, Glu-197 to Ser-202, Arg-215 to Glu-221, Thr- 237 to Pro-242.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis or treatment of benign prostatic hypertrophy or prostate cancer.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders or injuries of the salivary gland.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of glandular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disorders of, or injuries to the salivary gland or other glandular tissue.
  • polypeptides of the invention comprise the sequence: DPRVRLNSLTCKHIFISLTQ (SEQ ID NO:583); TMKLLKLRRNIV KLSLYRHFTN (SEQ ID NO:576); TL-LAVAASIVFIIWTTMKFRI (SEQ ID NO:577); VTCQSDWRELWVDDAIWRLLFSMILFVI (SEQ ID NO:578); MVLWR PSANNQRFAFSPLSEEEEEDEQ (SEQ ID NO:580); KEPMLKESFEGMKMRS
  • TKQEPNGNSKVNKAQEDDL SEQ ID NO:584
  • KWVEENVPSSVTDVALP ALLDSDEERMITHFERSKME SEQ ID NO:582
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • This gene is expressed primarily in thyroid and to a lesser extent in osteoclastoma, kidney medulla, and lung.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, thyroid dysfunction or cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or cells e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 333 as residues: Lys-107 to Leu-
  • polypeptides of the invention comprise the sequence: IRHELTVLRDTRPACA (SEQ ID NO:585); and or MDFXMALIYD (SEQ ID NO:586). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • This gene is expressed primarily in kidney cortex and to a lesser extent in adult brain, corpus colosum, hippocampus, and frontal cortex.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment or diagnosis of neurological disorders.
  • polypeptides of the invention comprise the sequence: MQEMMRNQDRALSNLESIPGGYNA (SEQ ID NO:587); LRRMYTDIQEPMLSA AQEQF GGNPF (SEQ ID NO:588); ASLVSNTSSGEGSQPSRTENRDPLPNPWAP QT (SEQ ID NO:589); SQSSSASSGTASTVGGTTGSTASGTSGQSTTAPNLVPGV GASMFNTPG MQSLLQQITENPQLMQNMLSAPY (SEQ ID NO:590); MRSMMQSLSQNPDL-AAQIv-MLNNPLFAGNPQLQEQMRQQLPTFLQQ (SEQ ID NO:591 ); MQNPDTLSAMSNPRAMQALLQIQQGLQTLATEAPGLIPGFTPGLG ALGSTGGSSGTNGSNATPSENTSPTAGT (SEQ ID NO:592); TEPGHQQFI
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, breast cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of some types of breast cancer.
  • polypeptides of the invention comprise the sequence: NLCHVDCQDLLNPNLLAGIHCAKRIVS (SEQ ID NO:602); LDGFEGYSLSDWLCLAFVESKFN (SEQ ID NO:603); NENADGSFDYGLFQINSHYWCN (SEQ ID NO:604); and/or
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infection.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g.. serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g. serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 336 as residues: Ile-62 to Phe-70, Asn- 78 to Asn-84.
  • tissue distribution and homology to lysozyme C precursor indicates that polynucleotides and polypeptides corresponding to this gene are useful for boosting the moncyte-macrophage system and enhance the activity of immunoagents.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of some immune disorders.
  • the translation product of this gene shares sequence homology with ARI protein of Drosophila (accession 2058299; EMBL: locus DMARIADNE, accession
  • polypeptides of the invention comprise the sequence IREVNEVIQNPAT (SEQ ID NO:606); ITR1-LLSHFNWDKEKLMERYF DGNLEKLFA (SEQ ID NO:607); NTRSSAQDMPCQICYLNYPNSYF (SEQ ID NO:608); TGLECGHKFCMQCWSEYLTTKIMEEGMGQTISCPAHG (SEQ ID NO:614); CD-LVDDNTVMRLITDSKVKLKYQHLITNSFVECNRLLKWCPAPD CHHVVKVQYPDAKPV (SEQ ID NO:609); CDILVDDNTVMRL-TDSK VKLKYQHLITNSFVECNRLLKWCPAPDCHHVVKV (SEQ ID NO:610); GCNHMVCRNQNCKAEFCWVCLGPWEPHGSAWYNCNRYNEDDAKAARD
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases or injuries involving axonal path development.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to ARI protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of disease states or injuries involving axonal path development, including neurodegenerative diseases and nerve injury.
  • the translation product of this gene shares sequence homology with cytochrome b561 [Sus scrofa] which is thought to be an integral membrane protein of neuroendocrine storage vesicles of neurotrans itters and peptide hormones.
  • This gene is expressed primarily in frontal cortex and to a lesser extent in rhabdomyosarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 339 as residues: Ser-18 to Pro-24.
  • tissue distribution and homology to cytochrome b561 indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of neurological disorders. This gene may also be important in regulation of some types of cancers.
  • polypeptides of the invention comprise the sequence: MWGYLFVDAAWNFLGCLICGW (SEQ ID NO:615); MHFISSGNVSAIRSSILLL RXSLSYLGNCLRVSAIFVYFLLFLLLS (SEQ ID NO:616); and/or MDQALRGSPSE GFSTDPSPPQVGRQIPSFPPWRRLVLPKASGCFLEREWWLCVFKLRTRPGAEA HAYNSSILGGRGKGIT (SEQ ID NO:617). Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pancreatic tumors.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the endocrine system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 340 as residues: Pro-22 to Phe-33.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of pancreatic tumors.
  • polypeptides of the invention comprise the sequence: MLP- -LASCCHFSPPEQAA- ⁇ KKLQEQEKQQKVE- ⁇ K-RMEKEVSD ⁇ QDSGQIK KKFQPMNK-ERSILHDVVEVAGLTSFSFGEDDDCRYVMIFKKEFAPSDEELDSY RRGEEWDPQKAEEKRNXKELAQRQ (SEQ ID NO:618); EEEAAQQGPVVV SPASDY--DKYSHLIGKGAAK-DAAI-MLQANKTYGCXPVANKr ⁇ TRSffiEA-MNE IRAKKRLRQSGE (SEQ ID NO:619); PPRRPAQLPLTPGAGQGAGRDKAAAIRA HPGAPPLNHLLP (SEQ IDNO:620); AVPQAGGKQVFDLSPLELGY
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders, especially involving acrosomal disfunction.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 341 as residues: Glu-8 to Asn-35.
  • tissue distribution and homology to FSA-1 indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of infertility due to acrosomal disfunction of sperm.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, male reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 342 as residues: Met-1 to Trp-6.
  • the gene is found in both pituitary and epididymus, this indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of male reproductive disorders. This may involve a secreted peptide produced in the pituitary targeting the epididymus.
  • polypeptides of the invention comprise the sequence:
  • polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in resting T-cells. . Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, T-cell disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of certain immune disorders, especially those involving T-cells.
  • FEATURES OF PROTEIN ENCODED BY GENE NO: 111 This gene is expressed primarily in cerebellum and whole brain and to a lesser extent in infant brain and fetal kidney.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 344 as residues: Asp-48 to Gly-55.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurological disorders.
  • the translation product of this gene shares sequence homology with yeast mitochondrial ribosomal protein homologous to ribosomal protein sl5 of E.coli which is thought to be important in the early assembly of ribosomes (See Accession No. M38016).
  • This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development of cancers and tumors in addition to healing wounds.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissues or cells particularly of the immune and developmental expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to ribosomalprotein sl5 of E. coli indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases related to the assembly of ribosomes in the mitochondria which is important in the translation of RNA into protein. Therefore, this indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of multiple tumors as well as in healing wounds which are thought to be under similar regulation as developmental tissues. Protein, as well as, antibodies directed against the protein have utility as tumor markers, in addition to immunotherapy targets, for the above listed tumors and tissues.
  • polypeptide fragments comprise the following amino acid sequence: ELSISISNV-ALADEGEYTCSIFTMPVRTAKSLVTVLGIPQKPIITGYKSSLREKDT ATLNCQSSGSKPAARLTWRKGDQELHGEPTRIQEDPNGKTFTVSSSVTFQVTR EDDGASIVCSVNHESLKGADRSTSQRffiVLYTPTAMIRPDPPHPREGQKLLLHC EGRGNPVPQQYLWEKEGSVPPLKMTQESALIFPFLNKSDSGTYGCTATSNMGS YKAYYTLNVND (SEQ ID NO:625).
  • polynucleotide fragments encoding these polypeptide fragments See Accession No. gnllPIDIdl002627. This gene is expressed almost exclusively in human brain tissue. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, susceptibility to viral disease and diseases of the CNS especially cancers of that system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 346 as residues: Leu-26 to Asp-37, Lys- 53 to Ser-59.
  • tissue distribution and homology to poliovirus receptor precursors indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and prevention of diseases that involve the binding and uptake of virus particles for infection. It might also be helpful in genetic therapy where the goal is to insert foreign DNA into infected cells. With the help of this protein, the binding and uptake of this foreign DNA might be aided. In addition, it is expected that over expression of this gene will indicate abnormalities involving the CNS, particularly cancers of that system.
  • the translation product of this gene shares sequence homology with YO87_CAEEL hypothetical 28.5 KD protein ZK1236.7 in chromosome III of Caenorhabditis elegans in addition to alpha- 1 collagen type III (See Accession No. gil537432).
  • One embodiment for this gene is the polypeptide fragment(s) comprising the following amino acid sequence: VPELPDRVHQLHQAVQGCALGRPGFPGGPTH SGHHKSHPGPAGGDYNRCDRPGQVHLHNPRGTGRRGQLHPTAGPGVHRRA CPSQQLPHRLGPGVPCPSPSLTPVLPSWTQSWCG LPGYTSSS (SEQ ID NO:630).
  • An additional embodiment is the polynucleotide fragment(s) encoding these polypeptide fragments
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegeneration and imunological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neural and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 347 as residues: Glu-34 to Glu-39, Gly-51 to Ser-72, Ala-88 to Glu-93, Gin- 100 to Val-
  • tissue distribution and homology to YO87_CAEEL hypothetical 28.5 KD protein ZK1236.7 in chromosome III of Caenorhabditis elegans as well as to a conserved alpha- 1 collagen type III protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons' Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorders. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • the translation product of this gene shares sequence homology with alpha 3 type IX collagen which is thought to be important in hyaline cartilage formation via its ability to uptake inorganic sulfate by cells (See Accession No. gil975657).
  • This gene is the polypeptide fragment comprising the following amino acid sequence: SLRRPRSAAXQTLTTFLSSVSSASSSALPGSREPCDPRAPPPPR SGSAASCCSCCCSCPRRRAPLRSPRGSKRRIRQREVVDLYNGMCLQGPAGVPG RDGSPGANGIPGTPGIPGRDGFKGEKGECLRESFEESWTPNYKQCSWSSLNY GIDLGKIAECTFTKMRSNSALRVLFSGSLRLKCRNACCQRWYFTFNGAECSGP LPIEAIIYLDQGSPEMNSTINIHRTSSVEGLCEGIGAGLVDVAIWVGTCSDYPKG DASTGWNSVSRIIIEELPK (SEQ ID NO:634).
  • An additional embodiment are the polynu
  • This gene is expressed primarily in smooth muscle and to a lesser extent in synovial tissue.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e., spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid and autoimmune disorders .
  • diseases and conditions include, but are not limited to, dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e., spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid and
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual
  • tissue distribution and homology to alpha 3 type IX collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases associated with the mutation in this gene which leads to the many different types of chondrodysplasias.
  • this product the abnormal growth and development of bones of the limbs and spine could be routinely detected or treated in utero since the protein or muteins thereof could affect epithelial cells early in development and later the chondrocytes of the developing craniofacial structure.
  • the translation product of this gene shares sequence homology with retro virus-related reverse transcriptase which is thought to be important in viral replication.
  • One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: TKKENCRPASLMNIDTKILNKILMNQ (SEQ ID NO:640).
  • An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments (See Accession No. pirlA25313IGNHULl).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, retroviral diseases such as AIDS, and possibly certain cancers due to transactivation of latent cell division genes.
  • diseases and conditions which include, but are not limited to, retroviral diseases such as AIDS, and possibly certain cancers due to transactivation of latent cell division genes.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to retrovirus-related reverse transcriptase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of diseases and maladies associated with retroviral infection since a functional reverse transcriptase (RT) or RT-like molecule is an integral component of the retroviral life cycle.
  • RT reverse transcriptase
  • the translation product of this gene shares sequence homology with an unknown gene from C. elegans, as well as weak homolog with mammalian metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is known to be required for embryonic development.
  • Preferred polypeptide fragments comprise the following amino acid sequence: MCNLPIKVVCRANAEYMSPSGKVPXXHVGNQ VVSELGPIVQFVKAKGHSLSDGLEEVQKAEMKAYMELVNNMLLTAELYLQWC DEATVGXITHXRYGSPYPWPLXHILAYQKQWEVKRKXKAIGWGKKTLDQVLE DVDQCCQ- ⁇ SQRLGTQPYFFNKQPTELDALVFGHLYTILTTQLTNDELSEKVKN YSNLLAFCRRI EQHYFEDRGKGRLS (SEQ ID NO:641); MCNLPIKVVCRANAE YMSPSGKVPXXHVGNQVVSELGPIVQFVK (SEQ ID NO:642),.
  • polypeptide fragments encoding these polypeptide fragments (See Accession No. gill326108). This gene is expressed primarily in fetal tissues and to a lesser extent in hematopoietic cells and tissues, including spleen, monocytes, and T cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer; lymphoproliferative disorders; inflammation; chondrosarcoma, and Gaucher disease.
  • diseases and conditions which include, but are not limited to, cancer; lymphoproliferative disorders; inflammation; chondrosarcoma, and Gaucher disease.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hematopoietic and embryonic systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders.
  • Expression in embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation or cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and survival of hematopoietic cell lineages.
  • this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells.
  • the translation product of this gene shares sequence homology with reverse transcriptase which is important in the synthesis of a cDNA chain from an RNA molecule, and is a method whereby the infecting RNA chains of retroviruses are transcribed into their DNA complements.
  • One embodiment for this gene is the polypeptide fragment comprising the following amino acid sequence: MXXXNSHITIFTLNVNGLNAPNERHRLANWIQSQDQVCCIQETHLTGRDTHRL KIKGWRKIYQANGKQKK (SEQ ID NO:647).
  • An additional embodiment is the polynucleotide fragments comprising polynucleotides encoding these polypeptide fragments (See Accession No. gil2072964).
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, hematopoietic disorders; inflammation; disorders of immune surveillance.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution and homology to reverse transcriptase indicates that polynucleotides and polypeptides corresponding to this gene are useful for cancer therapy.
  • Expression in the skin also indicates that this gene is useful in wound healing and fibrosis.
  • Expression by neutrophils also indicates that this gene product plays a role in inflammation and the control of immune surveillance (i.e. recognition of viral pathogens).
  • Reverse transcriptase family members are also useful in the detection and treatment of AIDS.
  • the translation product of this gene shares sequence homology with reverse transcriptase which is important in the synthesis of a cDNA copy of an RNA molecule, and is a method whereby a retrovirus reverse-transcribes its genome into an inheritable DNA copy.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and neurodegenerative disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the CNS and peripheral nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • this gene has homology to a hypothetical protein in Schizosaccharomyces pombe (See Accession No. 2281980).
  • Another embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: IYHLHSWIFFHFKRAFCMCFITMKVIHAHCSKLRKCXNAQISVFCTTLTASYPT (SEQ ID NO:651).
  • An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments. This gene maps to chromosome 18, and therefore, may be used as a marker in linkage analysis for chromosome 18.
  • This gene is expressed primarily in adult hypothalamus and to a lesser extent in infant brain.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative disorders; endocrine function; and vertigo.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the brain, CNS and peripheral nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of neurodegenerative disorders; diagnosis of tumors of a brain or neuronal origin; treatments involving hormonal control of the entire body and of homeostasis, behavioral disorders, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo.
  • IRLB protein which is thought to be important in binding to a c-myc promoter element and thus regulating its transcription (See Accession No. gil33969). This gene maps to chromosome 1 , and therefore, may be used as a marker in linkage analysis for chromosome 1.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer of the brain and breast; lymphoproliferative disorders; neurodegenerative diseases.
  • diseases and conditions include, but are not limited to, cancer of the brain and breast; lymphoproliferative disorders; neurodegenerative diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the CNS, breast, and immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cancer of the brain, breast, and hematopoietic system. In addition, it may be useful for the treatment of neurodegenerative disorders, as well as disorders of the hematopoietic system, including defects in immune competency and inflammation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.
  • the translation product of this gene shares sequence homology with an ATP synthase, a key component of the proton channel that is thought to be important in the translocation of protons across the membrane. This gene is expressed primarily in T cell lymphoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, T cell lymphoma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to ATP synthase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of defects in proton transport, homeostasis, and metabolism, as well as the diagnosis and treatment of lymphoma.
  • the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer (abnormal cell proliferation); T cell lymphomas; and hematopoietic disorders.
  • diseases and conditions which include, but are not limited to, cancer (abnormal cell proliferation); T cell lymphomas; and hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the fetus and immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions involving cell proliferation.
  • Expression of this gene in fetal tissues, as well as in a variety of blood cell lineages indicates that it may play a role in either cellular proliferation; apoptosis; or cell survival. Thus it may be useful in the management and treatment of a variety of cancers and malignancies.
  • its expression in blood cells suggest that it may play additional roles in hematopoietic disorders and conditions, and could be useful in treating diseases involving autoimmunity, immune modulation, immune surveillance, and inflammation..
  • This gene is expressed primarily in placenta and to a lesser extent in pineal gland and rhabdomyosarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental, endocrine, and female reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the [insert system where a related disease state is likely, e.g., immune] expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 357 as residues: Leu-69 to Val
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders in development.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.
  • This gene is expressed primarily in benign prostatic hyperplasia.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of benign prostatic hyperplasia.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of benign prostatic hyperplasia.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases involving premature apoptosis, and immunological and gastrointestinal disorders.
  • diseases and conditions which include, but are not limited to, diseases involving premature apoptosis, and immunological and gastrointestinal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders involving inappropriate levels of apoptosis, especially in immune cell lineages. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases (such as AIDS), and leukemia. FEATURES OF PROTEIN ENCODED BY GENE NO: 127
  • This gene is expressed primarily in Raji cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and T cell autoimmune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 360 as residues: Asp-23 to Gly-29.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of inflammation and T cell autoimmune disorders. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases (such as AIDS), and leukemia.
  • immunological disorders including arthritis, asthma, immune deficiency diseases (such as AIDS), and leukemia.
  • polypeptide fragments comprising the following amino acid sequence: EDDGFNRSIHEVILKNITWY SERVLTEISLGSLL- VV--RTIQYNIV-TRTRDKYLHTNCLAALANMSAQFRSLHQY AAQRIISLFSLLSKKHNKVLEQATQSLRGSLSSNDVPLPDYAQDLNVIEEVIRMM LEIINSCLTNSLHHNPNLVALLYKRDLFEQFRTHPSFQDIMQNIDLVISFFSSRLL QAGS (SEQ ID NO:657); EDDGFNRSIHEVILKNITWYSERVLTEISLGSLLILVV (SEQ ID NO:658); RTIQYNMTRTRDKYLHTNCLAALANMSAQFRSLHQYAAQ RIISLFSLLSKKHN (SEQ ID NO:659); KKHNKVLEQATQSLRGSLSSNDVPLPDY AQD (SEQ ID NO.661 ); SCLTNSLHHNPNLVYALLYK
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, atherosclerosis and other cardiovascular and hepatic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the circulatory system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of circulatory system disorders such as atherosclerosis, hypertension, and thrombosis .
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells).
  • liver disorders and cancers e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.
  • PROTEIN ENCODED BY GENE NO: 129 The translation product of this gene shares sequence homology with a ribosomal protein which is thought to be important in cellular metabolism, in addition to the C.elegans protein F40F11.1 which does not have a known function at the current time (See Accession No. gnllPIDIe244552 ).
  • Preferred polypeptide fragments comprise the following amino acid sequence: MADIQTEI-AYQKQPT-PQNKKRVLLGETGKEKLPRVTNKNIGLGFKDT
  • PRRLLRGTYIDKKCPFTGNVSIRGRILSGVVTQDEDAEDHCHPPRLSALHPQVQ PLREAPQEHVCTPVPL LQGRPDR (SEQ ID NO:662); MKMQRTIVIRRDYLH YIRKYNRFEKRHKNMSVHLSPCFRDVQIGDIVTVGECRPLSKTVRFNVLKVTK AAGTKKQFQKF (SEQ ID NO:663); MADIQTERAYQKQPTIFQNKKRVLLGET GK (SEQ ID NO:664); HCHPPRLSALHPQVQPLREAPQEHVCTPVPL LQGRPDR (SEQ ID NO:666); NIGLGFKDTPRRLLRGTYIDKKCPFTGNVSIRGRILSGVVTQ (SEQ ID NO:669); MKMQRTIVIRRDYLHYIRKYNRFEKRHKNMSVHLSP (SEQ ID NO:667); CFRDVQIGDIVTVGECRPLSKTVRF
  • This gene is expressed primarily in Wilm's tumor and to a lesser extent in thymus and stromal cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases affecting RNA translation.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the Wilm's tumors
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or homology to a ribosomal protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases affecting RNA translation.
  • DNA helicase which is thought to be important in global transcriptional regulation (See Accession No. gnllPIDIe243594).
  • This gene is the polypeptide fragments comprising the following amino acid sequence: IFYDSDWNPTVDQQA MDRAHRLGQTKQVTVYRLICKGTIEERILQRAKEKSEIQRMVISG (SEQ ID NO:670); TRMIDLLEEYMVYRK-HTYXRLDGSSKISERRDMVADFQNRNDI FVFLLSTRAGGLGINLTAXDTVHF (SEQ ID NO:671); TRMIDLLEEYMVYRK HTYXRLDGSSKISERRDM (SEQ ID NO:674); RRDMVADFQNRNDIFVFLL STRAGGLGINLTAXDTVHF (SEQ ID NO:675) , IFYDSDWNPTVDQQAMD RAHRLGQTKQVTVYRLICKG (SEQ ID NO:676); RLICKGTIEERILQRAK EKSEIQRMVISG
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases and disorders of the brain.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to a DNA helicase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases affecting RNA transcription, particularly developmental disorders and healing wounds since the later are though to approximate developmental transcriptional regulation.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate enlargement and gastrointestinal disorders, particularly of the pancreas and gall bladder.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of prostate diseases, including benign prostatic hyperplasia and prostate cancer.
  • the tissue distribution in tumors of the pancreas indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tissues where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, pulmonary diseases and neurological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the pulmonary and respiratory systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of pulmonary and respiratory disorders such as emphysema, pneumonia, and pulmonary edema and emboli.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cirrhosis of the liver and other hepatic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the digestive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver disorders such as cirrhosis, jaundice, and Hepatitus.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
  • This gene is expressed primarily in fetal kidney and to a lesser extent in fetal liver and spleen.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, development and regeneration of liver and kidney and immunological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the digestive and excretory systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 367 as residues: Pro-70 to Arg-77,
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the kidney and liver, such as cirrhosis, kidney failure, kidney stones, and liver failure, hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • diseases of the kidney and liver such as cirrhosis, kidney failure, kidney stones, and liver failure, hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells.
  • the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.
  • This gene is expressed primarily in brain, bone marrow, and to a lesser extent in placenta, T cell, testis and neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative and immunological diseases and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the nervous and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 368 as residues: Met-1 to His-6.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.
  • This gene is expressed primarily in placenta, embryo, T cell and fetal lung and to a lesser extent in endothelial, tonsil and bone marrow.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological and developmental diseases in addition to cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 369 as residues: Gly-19 to Gln-28, Pro-36 to Phe-42.
  • tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • This gene is expressed primarily in TNF and INF induced epithelial cells, T cells and kidney.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory conditions particularly inflammatory reactions in the kidney.
  • diseases and conditions which include, but are not limited to, inflammatory conditions particularly inflammatory reactions in the kidney.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 370 as residues: Thr-67 to Gly-72, Gin- 132 to Ala- 145, Arg-150
  • This gene maps to chromosome 1, and therefore, may be used as a marker in linkage analysis for chromosome 1 (See Accession No. D63485).
  • This gene is expressed primarily in breast cancer and colon cancer and to a lesser extent in thymus and fetal spleen.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers, especially of the breast and colon tissues.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in tumors of colon and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • This gene maps to chromosome 17, and therefore, can be used as a marker for linkage analysis from chromosome 17.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunologically related diseases and hematopoietic disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system and hematopoietic system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in CD34, T-cell and neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of hematopoietic disorders and immunologically related diseases, such as anemia, leukemia, inflammation, infection, allergy, immunodeficiency disorders, arthritis, asthma, immune deficiency diseases such as AIDS.
  • hematopoietic disorders and immunologically related diseases such as anemia, leukemia, inflammation, infection, allergy, immunodeficiency disorders, arthritis, asthma, immune deficiency diseases such as AIDS.
  • Preferred polypeptide fragments comprise the amino acid sequence:
  • polynucleotide fragments encoding these polypeptide fragments.
  • This gene maps to chromosome 4, and therefore, may be used as a marker in linkage analysis for chromosome 4 (See Accession No. AB002311 ).
  • This gene is expressed primarily in ovarian cancer, tumors of the Testis, brain, and colon.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, ovarian, testicle, brain and colon cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the male and female reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in tumors of colon, ovary, testis, and brain origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, colon cancer and immunological disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the gastrointestinal trace and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in tumors of colon, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • T cell translocation protein a putative zinc finger factor (See Accession No. 340454), as well as to the G-protein coupled receptor TM5 consensus polypeptide (See Accession No. R50734).
  • Preferred polypeptide fragments comprise the following amino acid sequence:
  • CLLFVFVSLGMRCLFWTIVYNVLYLKHKCNTVLLCYHLCSI (SEQ ID NO:687); ACS--LIPAF ⁇ MVMRAKDNVYHLDCFACQLCNQRXCVGDKFFLKNNXXLCQT DYEEGLMKEGYAPXVR (SEQ ID NO:688).
  • polynucleotide fragments encoding these polypeptide fragments This gene is expressed primarily in fetal brain.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological disorders including brain cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the Central Nervous System
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo.
  • Fas ligand which is a cysteine-rich type II transmembrane protein/tumor necrosis factor receptor homolog. Mutations within this protein have been shown to result in generalized lymphoproliferative disease leading to the development of lymphadenopathy and autoimmune disease (See Medline Article No. 94185175).
  • Preferred polypeptide fragments comprise the following amino acid sequence:
  • SALSEPGAPDRRRPCPESVPRRPDDEQWPPPTALCLDVAPLPPSS (SEQ ID NO:689).
  • polynucleotide fragments encoding these polypeptide fragments See Accession No. 473565. This gene is expressed primarily in osteoblasts, lung, and brain.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoblast-related, pulmonary, neurological, and immunological diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the skeletal and nervous systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 376 as residues: Trp-33 to Thr-40, Lys- 45 to Ile-63.
  • the tissue distribution in osteoblasts, lung, and brain combined with its homology to the Fas ligand indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • the Fas ligand gene is known to be expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including asthma, immune deficiency diseases such as AIDS and leukemia, and various autoimmune disorders including lupus and arthritis.
  • Preferred polypeptide fragments comprise the amino acid sequence:
  • This gene is expressed primarily in osteoclastoma, hemangiopericytoma, liver, lung.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, osteoclastoma, hemangiopericytoma, liver and lung tumors.
  • diseases and conditions which include, but are not limited to, osteoclastoma, hemangiopericytoma, liver and lung tumors.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the above tissue(s) or cell type(s).
  • tissue or cells particularly of the lung and liver systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing osteoclastoma, hemangiopericytoma, liver and lung tumors.
  • An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, brain, kidney, colon, and testicular cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive system, neurological, circulatory, and gastrointestinal systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in tumors of brain, kidney, colon, and testis origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.
  • the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.
  • the translation product of this gene shares sequence homology with goliath protein which is thought to be important in the regulation of gene expression during development. Protein may serve as a transcription factor.
  • This gene is the polypeptide fragments comprising the following amino acid sequence: TEH ⁇ AVM ⁇ TELRGKDILSYLEKNISVQMTIAVGTRMPPKNFSRGSLVFVSISFIV
  • polynucleotide fragments encoding these polypeptide fragments See Accession No. 157535.
  • another embodiment is the polynucleotide fragments encoding these polypeptide fragments: MTHPGTEHIIAVMITELRG--D-LSYLEKNISVQMTIAVGTRMPPKNFSRGS
  • An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments.
  • supernatants removed from cells containing this gene activated the GAS pathway.
  • this gene activates immune cells through the JAKS/STAT signal transduction pathway.
  • This gene is expressed primarily in macrophage, breast, kidney and to a lesser extent in synovium, hypothalamus and rhabdomyosarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, schizophrenia and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune and neural system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution and homology to zinc finger protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of schizophrenia, kidney disease and other cancers.
  • the tissue distribution in macrophage, breast, and kidney origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of tumors within these tissues, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • polypeptide fragments comprising the following amino acid sequence: MSGQGLAGFFASVAMICAIASGSELSESAFGYF-TACAVIILTIICYLGLPRLEFYR YYQQLKLEGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILK NISVLAFSVCFIFTITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLG RSLTAVFMWPGKDSRWLPSWXLARLVFVPLLLLCNIKPRRYLTVVFEHDAW ⁇ FFMAAFAFSNGYLASLCMCFGPKKVKPAEAETAEPSWPSSCVWVWHWGLFS PSCSGQLCDKGWTEGLPASLPVCLLPLPSARGDPEWSGGFFF (SEQ ID NO:705); MSGQGLAGFFASVAMICAIASGSELSESAFGYFITACAVIILT ⁇ C YLGLPRLEFYRYYQQLKLE GPGEQETKLDLISKGEEPRA
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic disease.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the circular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to HNP36 protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of blood neoplasias and other hematopoietic disease.
  • This gene is expressed primarily in breast cancer cell lines, thymus stromal cells, and ovary.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, endocrine and female reproductive system diseases including breast cancer.
  • diseases and conditions which include, but are not limited to, endocrine and female reproductive system diseases including breast cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of endocrine disorders.
  • tissue distribution in tumors of thymus, ovary, and breast origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.
  • Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tumors and tissues
  • Translation product of this gene has homology to pmtl and pmt 2, two conserved schizosaccharomyces pombe genes.
  • One embodiment for this gene is the polypeptide fragments comprising the following amino acid sequence: DDDGreiVPffiDPAKH------DPEGLALGAVIASSKKAKRDLIDNSFNRYTFNEDEG ELPEWFVQEEKQHRIRQLPVGKKEVEHYRKRWREINARPIXXXXXXXXXXXXXXXXXXXXXXXXXXXLEQTRKKAEAVVNTVDIXRTRES (SEQ ID NO:710); DDDGFEIVPffiDPA-_HR-XDPEGL-ALGAVIASSKKAKRDLIDNSFNRYTF (SEQ ID NO:71 1); KRWREINARPIXXXXXXXXXXXXXXXXXLEQTRKKAE AVVNTVDIXRTRES (SEQ ID NO-71
  • This gene is expressed primarily in retina and ovary and to a lesser extent in brreast cancer cell, epididymus and osteosarcoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal growth disorders, cancer and reproductive system disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neural and reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 382 as residues: Met-1 to Gly-7. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis or
  • TISDPMEED- QWKYCTDL-EEKDLEKLDLVIKYMKRLMQQSVE SVWNMAFDFILDNVQVVLQQTYGSTLKVT SEQ ID NO:716
  • An additional embodiment is the polynucleotide fragments encoding these polypeptide fragments. This gene is expressed primarily in 12 week embryo and to a lesser extent in hemangiopericytoma and frontal cortex.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth disorders and hemangiopericytoma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the circular and neural system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 383 as residues: Leu-4 to Lys-11.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of growth disorders, hemangiopericytoma and other soft tissue tumors.
  • polypeptide fragments comprise the following amino acid sequence: FCHDCKFPEASPAMNCEP (SEQ ID NO:717). Also preferred are polynucleotide fragments encoding these polypeptide fragments (See Accession No. R95250).
  • This gene is expressed primarily in neutrophils.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, lymphoma, immunodeficiency diseases, and cancers resulting from genetic instability.
  • diseases and conditions which include, but are not limited to, lymphoma, immunodeficiency diseases, and cancers resulting from genetic instability.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 384 as residues: Met-1 to Lys-6.
  • the tissue distribution in neutrophils and the sequence homology indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of Hodgkin's lymphoma, since the elevated expression and secretion by the tumor mass may be indicative of tumors of this type. Additionally the gene product may be used as a target in the immunotherapy of the cancer. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, infectious diseases and lymphoma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of inflammation and infectious diseases.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammation and infectious disease.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 386 as residues: Ser-11 to Pro-17.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of infectious diseases and inflammation.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, uterine, ovarian, brain, and liver cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the female reproductive system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution of this gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnostic or therapeutic uses in the treatment of the female reproductive system, obesity, and liver disorders, particularly cancer in the above tissues.
  • This gene maps to chromosome 3, and therefore, may be used as a marker in linkage analysis for chromosome 3 (See Accession No. D87452).
  • This gene is expressed in multiple tissues including brain, aortic endothelial cells, smooth muscle, pituitary, testis, melancytes, spleen, nertrophils, and placenta.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological disorders including immunodeficiencies, cancers of the brain and the female reproductive system, as well as cardiovascular disorders, such as atherosclerosis and stroke.
  • diseases and conditions include, but are not limited to, immunological disorders including immunodeficiencies, cancers of the brain and the female reproductive system, as well as cardiovascular disorders, such as atherosclerosis and stroke.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution suggest that polynucleotides and polypeptides corresponding to this gene are useful in treatment/detection of disorders in the nervous system, including schizophrenia, neurodegeneration, neoplasia, brain cancer as well as cardiovascular and female reproductive disorders including cancer within the above tissues.
  • Cytochrome b561 is a transmembrane electron transport protein that is specific to a subset of secretory vesicles containing catecholamines and amidated peptides. This protein is thought to supply reducing equivalents to the intravesicular enzymes dopamine-beta-hydroxylase and alpha-peptide amidase.
  • Preferred polypeptides of the invention comprise the amino acid sequence: M-AMEGYW] ⁇ ALLGSALLVGFLSVIFALVWVLHYREGLGWDGSALEFNWHP VLMVTGFVHQGI- IVYRLPWTWKCSKLLMKSIHAGLNAVAAILAnSVVAVFE NHNVNNIANMYSLHSWVGLIAVICYLLQLLSGFSVFLLPWAPLSLRAFLMPIHV YSGIVIFGTVIATALMGLTEKLIFSLRDPAYSTFPPEGVFVNTLGLLILVFGALIF WIVTRPQWKRPKEPNSTILHPNGGTEQGARGSMPAYSGNNMDKSDSEL NSEVAARKRNLALDEAGQRSTM (SEQ ID NO:724); as well as antigenic fragments of at least 20 amino acids of this gene and/or biologically active fragments.
  • polynucleotide fragments encoding these polypeptide fragments. This gene is expressed primarily in anergic T-cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune system and metabolism related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein product or RNA of this gene is useful for treatment or diagnosis of immune system and metabolic diseases or conditions including Tay-Sachs disease, phenylketonuria, galactosemia, various porphyrias, and Hurler's syndrome.
  • Preferred polypeptide fragments comprise the amino acid sequence: PGRAGPSPGLSLQLPAEPGHPAGNLAPL TSRPQPLCRIPAVPG (SEQ ID NO:725). Also preferred are polynucleotide sequences encoding this polypeptide fragment.
  • This gene is expressed primarily in HL-60 tissue culture cells and to a lesser extent in liver, breast, and uterus.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunological diseases, hereditary disorders involving the MHC class of immune molecules, as well as developmental disorders and reproductive disorders.
  • diseases and conditions include, but are not limited to, immunological diseases, hereditary disorders involving the MHC class of immune molecules, as well as developmental disorders and reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune and reproductive system expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or cells e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 390 as residues: Ser-39 to Gly-46, Leu- 49 to Ala-62.
  • tissue distribution and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hereditary MHC disorders and particularly autoimmune disorders including rheumatoid arthritis, lupus, scleroderma, and dermatomyositis, as well as many reproductive disorders, including cancer of the uterus, and breast tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, a variety of brain disorders, particularly those effecting mood and personality.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the brain and central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and/or diagnosis of a variety of brain disorders, particularly bipolar disorder, unipolar depression, and dementia.
  • This gene is expressed in a variety of tissues and cell types including brain, smooth muscle, kidney, salivary gland and T-cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers of a variety of organs including brain, smooth muscle, kidney, salivary gland and T-cells and cardiovascular disorders.
  • diseases and conditions include, but are not limited to, cancers of a variety of organs including brain, smooth muscle, kidney, salivary gland and T-cells and cardiovascular disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous, urinary, salivary, digestive, and immune systems
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in brain, smooth muscle, and T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of various neurological, and cardiovascular disorders, but not limited to cancer within the above tissues.
  • the gene product may be used as a target in the immunotherapy of the cancer. Because the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • the translation product of this gene shares sequence homology with collagen which is thought to be important in cellular interactions, extracellular matrix formation, and has been found to be an identifying determinant in autoimmune disorders. Moreover, this gene shows sequence homology with the yeast protein, Slslp, an endoplasmic reticulum component, involved in the protein translocation process in Yeast Yarrowia lipolytica. (See Accession No. 1052828; see also J. Biol. Chem. 271, 11668-11675 (1996).) With mouse, this same region shows sequence homology with the heavy chain of kinesin. (See Accession No. 2062607.) Recently, suppression of the heavy chain of kinesin was shown to inhibits insulin secretion from primary cultures of mouse beta-cells.
  • kinesin was found associated with drug resistance and cell immortalization. (See 468355.)
  • this gene also act as a genetic suppressor elements. This gene is expressed primarily in the greater omentum and to a lesser extent in a variety of organs and cell types including gall bladder, stromal bone marrow cells, lymph node, liver, testes, pituitary, and thymus.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of the endocrine, gastrointestinal, and immunological systems, including autoimmune disorders and cancers in a variety of organs and cell types.
  • diseases and conditions include, but are not limited to, disorders of the endocrine, gastrointestinal, and immunological systems, including autoimmune disorders and cancers in a variety of organs and cell types.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the immune and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 393 as residues: Asn-27 to Leu-47, Gln- 81 to Lys-88, Asp-93 to Lys-102, Asn-107 to Leu-1 16, Met- 129 to Glu-141, Glu-150 to Asp- 157, Lys-176 to Glu-185, Glu-333 to Tyr-349, Cys-393 to Leu-403, Gln-423 to Gly-429.
  • tissue distribution in within various endocrine and immunological tissues combined with the sequence homology to a conserved collagen motif indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of various autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus erthyematosus, scleroderma, dermatomyositis
  • rheumatoid arthritis lupus erthyematosus
  • scleroderma dermatomyositis
  • the gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • This gene has homology to the tissue inhibitor of metalloproteinase 2. Such inhibitors are vital to proper regulation of metalloproteins such as collagenases (See Accession No. P16368).
  • this gene maps to chromosome 17, and therefore, may be used as a marker in linkage analysis for chromosome 17 (See Accession No. PI 6368).
  • This gene is expressed primarily in several types of cancer including osteoclastoma, chondrosarcoma, and rhabdomyosarcoma and to a lesser extent in several non-malignant tissues including synovium, amygdala, testes, placenta.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, various types of cancer, particularly cancers of bone and cartilage, as well as various autoimmune disorders.
  • diseases and conditions which include, but are not limited to, various types of cancer, particularly cancers of bone and cartilage, as well as various autoimmune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the musculoskeletal system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in various cancers and the sequence homology to a collagenase inhibitor indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, a variety of brain disorders, including Down's syndrome, depression, Schizophrenia, and epilepsy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution in brain tissue indicates this gene is useful for diagnosis of various neurological disorders including, but not limited to, brain cancer. Additionally the gene product may be used as a target in the immunotherapy of cancer in the brain as well as for the diagnosis of metabolic disorders such as obesity Tay-Sachs disease, phenylketonuria and Hurler's Syndrome. FEATURES OF PROTEIN ENCODED BY GENE NO: 163
  • This gene is expressed primarily in placenta, neutrophils, and microvascular endothelial cells and to a lesser extent in multiple tissues including brain, prostate, spleen, thymus, and bone.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neutropenea and other diseases of the immune system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis various female reproductive disorders. Additionally the gene product may be used as a target in the immunotherapy of various cancers. Because the gene is expressed in some cells of lymphoid and endocrine origin, the natural gene product may be involved in immune functions and metabolism regulation, respectively. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • This gene is expressed primarily in neutrophils, monocytes, bone marrow, and fetal liver.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune system disorders including, but not limited to, autoimmune disorders such as lupus, and immunodeficiency disorders .
  • diseases and conditions which include, but are not limited to, immune system disorders including, but not limited to, autoimmune disorders such as lupus, and immunodeficiency disorders .
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in various immune system tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis of various immunological disorders such as Hodgkin's lymphoma, arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia.
  • polypeptide fragments comprise the following amino acid sequence:
  • polynucleotide fragments encoding these polypeptide fragments. Furthermore, this gene maps to chromosome 6, and therefore, may be used as a marker in linkage analysis for chromosome 6 (See Accession No. N62896).
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, musculoskeletal disorders including Muscular Dystrophy and cardiovascular diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the muscle tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to dystrophin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of Muscular Dystrophy and other muscle disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the central nervous system, including Alzheimer's Disease, Parkinson's Disease, ALS, and mental illnesses.
  • diseases and conditions which include, but are not limited to, diseases of the central nervous system, including Alzheimer's Disease, Parkinson's Disease, ALS, and mental illnesses.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of diseases of the central nervous system and may protect or enhance survival of neuronal cells by slowing progression of neurodegenerative diseases.
  • Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
  • This gene is expressed primarily in human testes tumor and to a lesser extent in normal human testes.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the testes, particularly cancer, and other reproductive disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the male reproductive tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • the tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of testicular diseases including cancers.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, conditions affecting hematopoietic development and metabolic diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hepatic system, and fetal hematopoietic system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 401 as residues: His-7 to Trp-17, Leu-19 to Lys-27, Pro-33 to Gly-44, Lys-68 to Gly-74, Lys-85 to Cys-95.
  • tissue distribution indicates that the protein products of this gene are useful for treatment/diagnosis of diseases of the developing liver and hematopoietic system, and act as a growth differentiation factor for hematopoietic stem cells.
  • polypeptide encoded by this gene is believed to be a membrane bound receptor.
  • deletions of either end of the extracellular domain up to the first cysteine from the N-terminus and the first cysteine of the C-terminus is expected to retain the biological functions of the full-length extracellular domain because the cysteines are thought to be responsible for providing secondary structure to the molecule.
  • deletions of one or more amino acids from either end (or both ends) of the extracellular domain are contemplated.
  • further deletions including the cysteines are also contemplated as useful as such polypeptides is expected to have immunological properties such as the ability to evoke and immune response.
  • Polynucleotides encoding all of the foregoing polypeptides are provided.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers, particularly those of the bone and connective tissues.
  • diseases and conditions which include, but are not limited to, cancers, particularly those of the bone and connective tissues.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the skeletal system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 402 as residues: Met-1 to Cys-6, Ala-41 to Tyr-49, Lys-76 to Lys-84.
  • the tissue distribution indicates that the protein products of this gene are useful for diagnosis of cancers of the bone and connective tissues, and may act as growth factors for cells involved in bone or connective tissue g er 1 owth.
  • polypeptides encoded by this gene comprising the following amino acid sequence: NSVPNLQTLAVLTEAIGPEPAIPRXPREPPVATSTPATPSAGPQPLPTGTV LVPGGPAPPCLGEAWALLLPPCRPSLTSCFWSPRPSPWKETGV (SEQ ID NO:733).
  • Polynucleotides encoding such polypeptides are also provided herein. This gene is expressed primarily in hematopoietic progenitor cells. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the blood including cancer and autoimmune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) particularly of the blood/circulatory system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 403 as residues: Gln-4 to His-10, Pro-25 to His-32.
  • the tissue distribution indicates that the protein products of this gene are useful for diagnosis of diseases involving growth differentiation of hematopoietic cells.
  • polypeptides encoded by this gene comprise the following amino acid sequences: ALQLAFYPDAVEEWLEENVHPSLQRLQXLLQDLSEVSAPP (SEQ ID NO:734); and/or CHPPALAGTLLRTPEGRAHARGLLLEAGGA (SEQ ID NO:735). Polynucleotides encoding such polypeptides are also provided. The protein product of this gene shares sequence homology with metallothionines. Thus, polypeptide encoded by this gene are expected to have metallothionine activity, such activities are known in the art and described elsewhere herein.
  • This gene is expressed primarily in kidney cortex.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the kidney including cancer and renal dysfunction.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the renal system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or cells e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 404 as residues: Ser-47 to Gln-52.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of diseases of the kidney including kidney failure.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the developing embryo, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 405 as residues: Gln-31 to Thr-43, Gly-51 to Ser-58, Pro-65 to Pro
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment/diagnosis of developmental problems with fetal tissue.
  • the gene may be involved in vital organ development in the early stage, especially hematopoiesis, cardiovascular system, and neural development.
  • the translation product of this gene shares sequence homology with TGN38, an integral membrane protein previously shown to be predominantly localized to the trans- Golgi network (TGN) of cells.
  • TGN trans- Golgi network
  • This gene is expressed primarily in developing embryo and to a lesser extent in cancer tissues including lymphoma, endometrial, protate and colon.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the developing fetus
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 406 as residues: His-65 to Ser-72, Pro-82 to Gly-91, Pro-98 to Glu-118, Ser-126 to Gly-166, Pro-180 to Asp-188, Tyr-209 to Lys-214, Gln-220 to Leu-228.
  • tissue distribution and homology to an integral membrane protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of cancers and developmental abnormalities where aberrant expression relates to an abnormality.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 407 as residues: Thr-13 to Trp-21, Arg- 74 to Asp-81.
  • tissue distribution and homology to dnaJ indicates that polynucleotides and polypeptides corresponding to this gene are useful as a diagnostic for cancer including Hodgkin's lymphoma.
  • This gene is expressed primarily in endothelial cells and to a lesser extent in bone marrow stromal cells.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases involving angiogenic abnormalities including diabetic retinopathy, macular degeneration, and other diseases including arteriosclerosis and cancer.
  • diseases and conditions which include, but are not limited to, diseases involving angiogenic abnormalities including diabetic retinopathy, macular degeneration, and other diseases including arteriosclerosis and cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the vascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that the protein products of this gene are useful for treating diseases where an increase or decrease in angiogenesis is indicated and as a factor in the wound healing process.
  • the translation product of this gene shares sequence homology with MAT8 (mouse) which is thought to be important in regulating chloride conductance in cells (particularly in the breast) by modulating the response mediated by c AMP and protein kinase C to extracellular signals.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, inflammatory responses mediated by T cells, macrophages, and/or neutrophils particularly those involving TNF, and also cancer.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 409 as residues: Thr-19 to Ala-33, Leu-54 to Asp-82, Pro-89 to Ala-97, Pro-100 to Lys-125, Ser-127 to Phe-135, Gly-164 to Leu-169, Cys-173 to Arg-178.
  • tissue distribution and homology to mat-8 indicates that polynucleotides and polypeptides corresponding to this gene are useful for modifying inflammatory responses to cytokines such as TNF and thus modifying the duration and/or severity of inflammation.
  • Polynucleotides and polypeptides derived from this gene are thought to be useful in the diagnosis and treatment of cancer.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, vascular restenosis.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the vascular system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating diseases associated with vascular response to injury such as vascular restenosis following angioplasty..
  • One embodiment of the claimed invention comprises: MRPDWKAGAGPGGPPQKPAPSSQRKPPARPSAAAAAIAVAAAEEERRLRQRN RLRLEEDKPAVERCLEELVFGDVENDEDALLRRLRGPRVQEHEDSGDSEVENEA KGNFPPQKKPVWVDEEDEDEEMVDMMNN--FR- ⁇ DMM- ⁇ ASESKLSKDNLKK RLKEEFQHAMGGVPAWAETTKRKTSSDDESEEDEDDLLQRTGNHSTSTSLPRG ILKMKNCQHANAERPTVARISICAVPSRCTDCDGCWD (SEQ ID NO:737); or CLEELVFGDVENDEDALLRRLRGPRVQEHEDSGDSEVENEAKGNFPPQKKPV WVDEEDEDEEMVDMMNNRFRKDMMKNASESKLSKDNLKKRLKEEFQHAMG GVPAWAETTKRKTSSDDESEEDEDDLLQRTGNFISTSTSLPRGILKMKNCQHA NAERPTVARISICA
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, tumors of the reproductive organs including testis and endometrial cells.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 411 as residues: Ser-67 to Lys-72, Val-87 to Leu-93, Tyr-128 to Pro-141
  • the tissue distribution indicates that the protein products of this gene are useful for treating tumors of the endometrium or epithelial tumors of the reproductive system.
  • Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
  • the translation product of this gene shares sequence homology with neuropsin a novel serine protease which is thought to be important in modulating extracellular signaling pathways in the brain. Owing to the structural similarity to other serine proteases the protein products of this gene are expected to have serine protease activity which may be assayed by methods known in the art and described elsewhere herein.
  • This gene is expressed primarily in endometrial tumor and to a lesser extent in colon cancer, benign hypertrophic prostate, and thymus.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers of the endometrium or colon and benign hypertrophy of the prostate.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the urogenital or reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 412 as residues: Gly-12 to Ser-22, Pro
  • tissue distribution and homology to serine proteases indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing or treating hperproliferative disorders such as cancer of the endometrium or colon and hyperplasia of the prostate.
  • Preferred polypeptide encoded by this gene comprise the following amino acid sequence: VLQGRYFSPILEMRRLRPEGXXNLPGGSRAQKEPRQDLTLVLWPHC PHFAMTRSYVPTKQCMVQGSFYCIFIFKGPVQNWC (SEQ ID NO:744).
  • Polynucleotides encoding such polypeptide are also provided. This gene is expressed primarily in fetal brain Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, identifying and expanding stem cells in the CNS.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue(s) or cell type(s) For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
  • tissue distribution indicates that the protein products of this gene are useful for detecting and expanding stem cell populations in the (or of the) central nervous system.
  • This gene is expressed primarily in early stage human brain and a stromal cell line.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, developmental abnormalities of the CNS.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the central nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or tissue distribution indicates that the protein products of this gene play a role in the development of the central nervous system. Therefore this gene and its products are useful for diagnosing or treating developmental abnormalities of the central nervous system.
  • Preferred polypeptides encoded by this gene comprise the following amino acid sequence:
  • This gene is expressed primarily in osteoclastoma, microvascular endothelium, and bone marrow derived cell lines.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematological diseases particularly involving aberrant proliferation of stem cells.
  • diseases and conditions which include, but are not limited to, hematological diseases particularly involving aberrant proliferation of stem cells.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 415 as residues: Ser-33 to Ala-39.
  • tissue distribution indicates that the protein products of this gene is useful for treating disorders of the progenitors of the immune system.
  • Applications include in vivo expansion of progenitor cells, ex vivo expansion of progenitor cells, or the treatment of tumors of the circulatory system, such as lymphomas.
  • polypeptides of the invention comprise the sequence: GFGSVSAAGRRSGGTWQPVQ (SEQ ID NO:747); PGGLAVGSRWWSRSLT (SEQ ID NO:748); LEPSRQRRPRRRGGTSRPETDQRAKCWRQL (SEQ ID NO:749); and/or VCLRCQNRMEN (SEQ ID NO:750).
  • polypeptides of the invention comprise the sequence: MAACTARRPGR GQPLVVPVADXGPVAKAALCAAXAGAFSPASTTTTRRHLSSRNRPEGKVLETV GVFEVPKQNGKYETGQLFLHSIFGYRGV VLFPWQ ARLXDRD V AS A APEKAEN PAGHGSKEVKGKTHTYYQVLIDARDCPHISQRSQTEAVTFLANHDDSRALYAIP GLDYVSHEDILPYTSTDQVPIQHELFERFLLYDQTKAPPFVAP-ETLRAWQEKNH PWLELSDVHRETTEMRVTVIPFYMGMREAQNSHVYWWRYCIRLENLDSDVVQ LRERHWRIFSLSGTLETVRGRGVVGREPVLSKEQPAFQYSSHVSLQASSGHMW GTFRFERPDGSHFDVRIPPFSLESNKDEKTPPSGLHW (SEQ ID NO:751); MAACTARRPGRGQPLVVPVADXGPVA
  • This gene is expressed primarily in gall bladder, prostate, and fetal brain, and to a lesser extent in a few tumor and fetal tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth related disorders such as cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of growth-related disorders, such cancers.
  • polypeptides of the invention comprise the sequence:SLCCPEGAEGC (SEQ ID NO:762) and/or QLKKTHYDRPCP (SEQ ID NO:763).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in stromal cell, tonsil, and glioblastoma and to a lesser extent in some other tissues.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune and inflammatory disorders and glioblastoma.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the stromal cells, tonsil, and glioblastoma expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Additionally, it is believed that the product of this gene regulates pancreatic cell differentiation into beta cells.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • tissue or cell sample taken from an individual having such a disorder
  • polynucleotides and polypeptides of the invention are useful in the treatment of insulin- dependent diabetes mellitus and associated conditions e.g. pancreatic hypofunction and the prevention, as well as the treatment of undifferentiated type pancreatic cancers.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 417 as residues: Pro-27 to Ala-32.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune and inflammatory disorders and glioblastoma.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, liver diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the liver
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • tissue or cell sample taken from an individual having such a disorder
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 418 as residues: Gly-32 to Lys-39.
  • the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of liver diseases.
  • polypeptides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neutronal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the hippocampus
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, bone-related disorders and neuronal diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the bone, ostoeclast, and hippocampus
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of bone-related disorders and neuronal diseases.
  • This gene maps to chromosome 4 and therefore polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 4.
  • This gene is expressed primarily in neuronal tissues such as hippocampus, spinal cord, and hypothalamus and to a lesser extent in a few other tissues such as ovary.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neuronal tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal disorders.
  • This gene maps to chromosome 10, therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 10.
  • This gene is expressed primarily in neuronal tissues and immune tissues, and to a lesser extent in a few other tissues such as skin tumor, lung etc.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neuronal and immune-related disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the neuronal and immune-related tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 422 as residues: Pro- 19 to Asp-25.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuronal and immune-related disorders.
  • polypeptides of the invention comprise the sequence: AQRK-KEMVLSEKVSQLMEWTN--- ⁇ VIRMNGDI ⁇ J--- ⁇ V-- ⁇ PPRNYSVIVMFTA LQLHRQCVVCKQADEEFQILANSWRYSSAFTNRIFFAMVDFDEGSDVFQMLNM NSAPTFINFPAKGKPKRGDTYELQVRGFSAEQIARWIADRTDVNIRVIRPPNMA ARWRFWCVSVT (SEQ ID NO:765); MVVALLIVCDVPSAS (SEQ ID NO:766); AQRKKEMVLSEKVSQL (SEQ ID NO:767); MEWTNKRPVIRMNGDKF (SEQ ID-768); Rl ⁇ VK-APPRNYSVIVMFTALQLHRQCVVCKQADEEFQ
  • This gene is expressed primarily in infant adrenal gland prostate cell line and to a lesser extent in a few other tissues like liver, smooth muscle etc.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, prostate cancer and endocrine disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the prostate and adrenal gland
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or homology to N33 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment for prostate cancer and endocrine disorders.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 424 as residues: Trp-3 to Phe-9.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders.
  • This gene maps to chromosome 6, therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 6.
  • Neural activity and neurotrophins induce synaptic remodeling in part by altering gene expression.
  • This gene is believed to be a glycosylphoshatidylinositol-anchored protein encoded by a hippocampal gene and to possess neural activity.
  • This molecule is believed to be expressed in postmitotic-differentiating neurons of the developing nervous system and neuronal structures associated with plasticity in the adult. Message of this gene is believed to be induced by neuronal activity and by the activity-regulated neurotrophins BDNF and NT-3.
  • polypeptides of the invention comprise the sequence: DAVFKGFSDCLLKLGDS (SEQ ID NO:773); CQEGAKDMWDKLRKESKNLN (SEQ ID NO:774); VLLVSLSAALATWLSF (SEQ ID NO:775); MGLKLNGRYISLILAVQIAYLVQAVR AAGKCDAVFKGFSDCLLKLGDS (SEQ ID NO:776); PAAWDDKTNIKTVCTYW EDFHSCTVTALTDCQEGAKDMWDKLRKESKNLNIQGSLFELCGSGNGAAGSL LPAFPVLLVSLSAALATWLSF (SEQ ID NO:777); and/or MGLKLNGRYISLILA VQIAYLVQAVRAAGKCDAVFKGFSDCLLKLGDSXXXXPAAWDD
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, relating to reproductive disorders, cancers and neurological diseases.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells For a number of disorders of the above tissues or cells, particularly of the reproductive and neurological disorders, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue or bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 425 as residues: Asp-47 to Asp- 63, His-75 to Tyr-80, Pro-83 to
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of reproductive disorders such as endometrial tumors.
  • Expression of this gene in tissues of the CNS and its strong homology to Neuritin suggest that the protein product from this gene may also be used in the treatment and diagnosis of neurological disorders and in the regeneration of neural tissues, e.g., following injury.
  • the translation product of this gene shares sequence homology with tenascin which is thought to be important in development.
  • the translation product of this gene is believed to be a ligand of the fibroblast growth factor family. FGF ligand activity is known in the art and can be assayed by methods known in the art and disclosed elsewhere herein.
  • This gene is expressed primarily in endometrial tumors, and other types of tumors.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the cancer tissues
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 426 as residues: Gly-29 to Glu-34, Arg- 71 to Arg-76, Thr-176 to Cys-182, Gly-184 to Glu-199.
  • the tissue distribution and homology to tenascin indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancers.
  • polypeptides of the invention comprise the sequence: MNSAAGFSHLDRRERVLKLGESFEKQPRCASTLC (SEQ ID NO:779).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in fetal human lung and neutrophils. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, lung development and respiratory disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the respiratory system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution in fetal lung and neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of lung and immunity related diseases, for example, lung cancer, viral, fungal or bacterial infections (e.g. lesions caused by tuberculosis), inflammation (e.g. pneumonia), metabolic lesions etc.
  • lung cancer for example, lung cancer, viral, fungal or bacterial infections (e.g. lesions caused by tuberculosis), inflammation (e.g. pneumonia), metabolic lesions etc.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immunal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immunal disorders.
  • This gene maps to chromosome 5 and accordingly, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 5.
  • the translation product of this gene shares sequence homology with human M-phase phosphoprotein 4 which is thought to be important in phosphorylation and signal transduction processes.
  • polypeptides of the invention comprise the sequence: TIYPTEEELQAVQKIVSITERALKLVSD (SEQ ID NOJ8O); RALKGVLRV GVLAKGLLLRGDRNVNLVLLC (SEQ ID NO:781); ALAALRHAKWFQARAN GLQSCVIIIR-LRDLCQRVPTWS (SEQ ID NO:782); GDALRRVFECISSGIIL (SEQ ID NO:783); LAFRQIHKVLGMDPLP (SEQ ID NO:784); and/or TIYPTEEELQAVQ KIVSITERALKLVSDSLSEHEKNKNKNKEGDDKKEGGKDRALKGVLRVGVLAKG LLLRGDR VNLVLLCSEKPSKTLLSRIAENLPKQLAVISPEKYDIKCAVSEAAIIL NSCVEPKMQVTITLTSP ⁇ REENMREGDVTSGMVKDPPDVLDRQKCLDALAALR HAKWFQARANGLQSCV ⁇
  • DYDNF SEQ ID NO:785
  • Polynucleotides encoding these polypeptides are also encompassed by the invention.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders related to reproductive system and nervous system.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the reproductive system and nervous system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissues e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue distribution and homology to human M-phase phosphoprotein 4 indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive and nervous system disorders.
  • polypeptides of the invention comprise the sequence: MGSQHSAAARPSSCRRKQEDDRDG (SEQ ID NO:786); LLAEREQEEAIAQFPYVEFTGRDSITCLTC (SEQ ID NO:787); and/or QGTGYIPTEQVNELVALIPHSDQRLRPQRTKQYV (SEQ ID NO:788).
  • Polynucleotides encoding these polypeptides are also encompassed by the invention. This gene is expressed primarily in Human Primary Breast Cancer and to a lesser extent in Human Adult Spleen, Hodgkin's Lymphoma I, Salivary Gland.
  • polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and immunal disorders.
  • polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s).
  • tissue or cells particularly of the cancer and immune system
  • expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • tissue e.g., cancerous and wounded tissues
  • bodily fluids e.g., serum, plasma, urine, synovial fluid or spinal fluid
  • another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
  • Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 430 as residues: Ser-126 to Gly-138.
  • tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and immunal disorders.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP98926237A 1997-06-06 1998-06-04 207 menschliche sekretierte proteine Withdrawn EP1039801A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04001119A EP1428833A3 (de) 1997-06-06 1998-06-04 207 menschliche sekretierte Proteine

Applications Claiming Priority (147)

Application Number Priority Date Filing Date Title
US57635P 1997-05-05
US4889997P 1997-06-06 1997-06-06
US4891797P 1997-06-06 1997-06-06
US4891597P 1997-06-06 1997-06-06
US4896297P 1997-06-06 1997-06-06
US4896497P 1997-06-06 1997-06-06
US4888197P 1997-06-06 1997-06-06
US4889797P 1997-06-06 1997-06-06
US4897097P 1997-06-06 1997-06-06
US4889297P 1997-06-06 1997-06-06
US4897197P 1997-06-06 1997-06-06
US4897297P 1997-06-06 1997-06-06
US4937597P 1997-06-06 1997-06-06
US4889897P 1997-06-06 1997-06-06
US4887597P 1997-06-06 1997-06-06
US4902097P 1997-06-06 1997-06-06
US4889397P 1997-06-06 1997-06-06
US4888597P 1997-06-06 1997-06-06
US4888097P 1997-06-06 1997-06-06
US4888497P 1997-06-06 1997-06-06
US4937397P 1997-06-06 1997-06-06
US4888397P 1997-06-06 1997-06-06
US4889597P 1997-06-06 1997-06-06
US4891697P 1997-06-06 1997-06-06
US4937497P 1997-06-06 1997-06-06
US4887897P 1997-06-06 1997-06-06
US4889497P 1997-06-06 1997-06-06
US4896397P 1997-06-06 1997-06-06
US4887797P 1997-06-06 1997-06-06
US4894997P 1997-06-06 1997-06-06
US4901997P 1997-06-06 1997-06-06
US4888297P 1997-06-06 1997-06-06
US4890197P 1997-06-06 1997-06-06
US4890097P 1997-06-06 1997-06-06
US4887697P 1997-06-06 1997-06-06
US4897497P 1997-06-06 1997-06-06
US4889697P 1997-06-06 1997-06-06
US48899P 1997-06-06
US48971P 1997-06-06
US48883P 1997-06-06
US48949P 1997-06-06
US48916P 1997-06-06
US48877P 1997-06-06
US48972P 1997-06-06
US48970P 1997-06-06
US48885P 1997-06-06
US49373P 1997-06-06
US48892P 1997-06-06
US48894P 1997-06-06
US49375P 1997-06-06
US48964P 1997-06-06
US48901P 1997-06-06
US48900P 1997-06-06
US48897P 1997-06-06
US48878P 1997-06-06
US48893P 1997-06-06
US49020P 1997-06-06
US48884P 1997-06-06
US49019P 1997-06-06
US48876P 1997-06-06
US48880P 1997-06-06
US49374P 1997-06-06
US48917P 1997-06-06
US48974P 1997-06-06
US48898P 1997-06-06
US48881P 1997-06-06
US48896P 1997-06-06
US48915P 1997-06-06
US48895P 1997-06-06
US48882P 1997-06-06
US48963P 1997-06-06
US48875P 1997-06-06
US48962P 1997-06-06
US5764797P 1997-09-05 1997-09-05
US5777497P 1997-09-05 1997-09-05
US5764997P 1997-09-05 1997-09-05
US5777897P 1997-09-05 1997-09-05
US5762997P 1997-09-05 1997-09-05
US5762897P 1997-09-05 1997-09-05
US5764697P 1997-09-05 1997-09-05
US5776597P 1997-09-05 1997-09-05
US5765497P 1997-09-05 1997-09-05
US5764297P 1997-09-05 1997-09-05
US5776197P 1997-09-05 1997-09-05
US5763497P 1997-09-05 1997-09-05
US5776997P 1997-09-05 1997-09-05
US5766897P 1997-09-05 1997-09-05
US5777097P 1997-09-05 1997-09-05
US5766297P 1997-09-05 1997-09-05
US5766697P 1997-09-05 1997-09-05
US5763597P 1997-09-05 1997-09-05
US5764397P 1997-09-05 1997-09-05
US5764497P 1997-09-05 1997-09-05
US5762797P 1997-09-05 1997-09-05
US5765097P 1997-09-05 1997-09-05
US5776397P 1997-09-05 1997-09-05
US5758497P 1997-09-05 1997-09-05
US5777197P 1997-09-05 1997-09-05
US5777697P 1997-09-05 1997-09-05
US5764897P 1997-09-05 1997-09-05
US5777797P 1997-09-05 1997-09-05
US5766197P 1997-09-05 1997-09-05
US5776497P 1997-09-05 1997-09-05
US5764597P 1997-09-05 1997-09-05
US5776297P 1997-09-05 1997-09-05
US5765197P 1997-09-05 1997-09-05
US5766797P 1997-09-05 1997-09-05
US5776097P 1997-09-05 1997-09-05
US5777597P 1997-09-05 1997-09-05
US57644P 1997-09-05
US57646P 1997-09-05
US57643P 1997-09-05
US57645P 1997-09-05
US57628P 1997-09-05
US57634P 1997-09-05
US57771P 1997-09-05
US57627P 1997-09-05
US57667P 1997-09-05
US57584P 1997-09-05
US57651P 1997-09-05
US57764P 1997-09-05
US57662P 1997-09-05
US57661P 1997-09-05
US57769P 1997-09-05
US57776P 1997-09-05
US57654P 1997-09-05
US57762P 1997-09-05
US57761P 1997-09-05
US57778P 1997-09-05
US57649P 1997-09-05
US57763P 1997-09-05
US57765P 1997-09-05
US57775P 1997-09-05
US57650P 1997-09-05
US57642P 1997-09-05
US57774P 1997-09-05
US57668P 1997-09-05
US57629P 1997-09-05
US57647P 1997-09-05
US57648P 1997-09-05
US57770P 1997-09-05
US57760P 1997-09-05
US57777P 1997-09-05
US57666P 1997-09-05
US7092397P 1997-12-18 1997-12-18
US70923P 1997-12-18
PCT/US1998/011422 WO1998054963A2 (en) 1997-06-06 1998-06-04 207 human secreted proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04001119A Division EP1428833A3 (de) 1997-06-06 1998-06-04 207 menschliche sekretierte Proteine

Publications (2)

Publication Number Publication Date
EP1039801A1 true EP1039801A1 (de) 2000-10-04
EP1039801A4 EP1039801A4 (de) 2003-03-26

Family

ID=27587074

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98926237A Withdrawn EP1039801A4 (de) 1997-06-06 1998-06-04 207 menschliche sekretierte proteine

Country Status (3)

Country Link
EP (1) EP1039801A4 (de)
CA (1) CA2291260A1 (de)
WO (1) WO1998054963A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043693A1 (en) 1998-02-26 1999-09-02 Human Genome Sciences, Inc. 36 human secreted proteins
WO2001062891A2 (en) * 2000-02-24 2001-08-30 Human Genome Sciences, Inc. 207 human secreted proteins
WO2000055371A1 (en) * 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
CA2285447A1 (en) * 1997-03-28 1998-10-08 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
WO1999007840A1 (en) * 1997-08-06 1999-02-18 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US7378507B2 (en) * 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
US6075136A (en) * 1998-02-17 2000-06-13 Incyte Pharmaceuticals, Inc. Prostate-associated serine protease
EP0939124A3 (de) * 1998-02-24 2001-03-21 Smithkline Beecham Plc MBGP1-Sequenzen
EP1056847A2 (de) * 1998-02-27 2000-12-06 Sagami Chemical Research Center Menschliche proteine mit transmembranären domäne und deren kodierende nukleinsäuren
WO1999047676A1 (en) * 1998-03-18 1999-09-23 Icos Corporation Human leupaxin polypeptide and dna encoding it, their uses
GB9807722D0 (en) * 1998-04-08 1998-06-10 Smithkline Beecham Plc Novel compounds
DE19818619A1 (de) * 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Blase-Tumor
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
CN1224710C (zh) * 1998-08-31 2005-10-26 余龙 一种新的人溶菌酶基因、其编码的多肽及制备方法
AU2003204358B2 (en) * 1998-09-01 2006-03-30 Genentech, Inc. Further pro polypeptides and sequences thereof
EP1121430A1 (de) * 1998-09-18 2001-08-08 Incyte Pharmaceuticals, Inc. Menschliches isre-bindendes protein
JP2002525117A (ja) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド Ｓｌｇｐタンパク質及び核酸分子並びにそれらの使用
US7414112B2 (en) 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US6020164A (en) * 1998-10-21 2000-02-01 Incyte Pharmaceuticals, Inc. Human RNA binding proteins
US6921658B1 (en) 1998-11-20 2005-07-26 Fuso Pharmacutical Industries, Ltd. Serine protease BSSP6
EP1144632A3 (de) * 1998-12-23 2001-11-07 Corixa Corporation Verbindungen zur immunotherapie und diagnose von dickdarmkrebs und verfahren zu ihrer anwendung
GB9828704D0 (en) 1998-12-24 1999-02-17 Nippon Glaxo Limited Proteins
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2361293A1 (en) * 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
WO2000058356A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
AU3396600A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002539776A (ja) * 1999-03-23 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
EP1177287A2 (de) * 1999-04-09 2002-02-06 Chiron Corporation Sekretierte menschliche proteine
WO2000061743A1 (fr) * 1999-04-09 2000-10-19 Shionogi & Co., Ltd. Gene associe a l'apoptose
AU4072300A (en) * 1999-04-09 2000-11-14 Human Genome Sciences, Inc. 50 human secreted proteins
EP1169447A1 (de) * 1999-04-15 2002-01-09 Osiris Therapeutics, Inc. Gene und expressionsprodukte aus haemapoetischen zellen
CA2371702A1 (en) * 1999-04-30 2000-11-09 Toshio Miyata Meg-3 protein
ATE323153T1 (de) * 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
AU4778600A (en) * 1999-05-20 2000-12-12 Takeda Chemical Industries Ltd. Novel polypeptide
AU5458300A (en) * 1999-06-07 2000-12-28 Human Genome Sciences, Inc. 26 human secreted proteins
EP1192171A4 (de) * 1999-06-11 2003-05-07 Human Genome Sciences Inc 48 menschliche sekretierte proteine
EP1185543A4 (de) * 1999-06-11 2003-09-03 Human Genome Sciences Inc 50 human-sekretierte proteine
AU5308200A (en) * 1999-06-11 2001-01-02 Human Genome Sciences, Inc. 48 human secreted proteins
EP1192176A4 (de) * 1999-06-11 2003-03-05 Human Genome Sciences Inc 49 menschliche sekretierte proteine
CA2378930A1 (en) * 1999-07-14 2001-01-25 Incyte Genomics, Inc. Electron transfer proteins
WO2001009317A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Gene associe au cancer de l'estomac
WO2001021794A2 (en) * 1999-09-20 2001-03-29 Ludwig Institute For Cancer Research Smad associating polypeptides
US6673570B1 (en) * 1999-09-20 2004-01-06 Ludwig Institute For Cancer Research Smad associating polypeptides
JP2003517297A (ja) * 1999-09-23 2003-05-27 ライジェル・ファーマシューティカルズ・インコーポレイテッド チェックポイント遺伝子関連細胞周期タンパク質、組成物および使用法
BR0015138A (pt) * 1999-10-28 2002-07-16 Warner Lambert Co Gene da esfingosina quinase humana
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
JP2003519491A (ja) * 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド
US6858427B2 (en) * 2000-02-14 2005-02-22 Genentech, Inc. Sphingosine kinases
CA2412408A1 (en) * 2000-07-24 2002-01-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors tr21 and tr22
AU2002223568A1 (en) * 2000-09-27 2002-04-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Identification of neuroblastoma tumor suppressor genes
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
WO2003000729A2 (en) * 2001-06-20 2003-01-03 Genentech, Inc. Secreted polypeptide and their use in the treatment of bone disorders
WO2003025135A2 (en) * 2001-09-14 2003-03-27 Gene Logic, Inc. Genes associated with malignant neoplasms
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017925A1 (en) * 1994-12-06 1996-06-13 Immunex Corporation Cytokine designated lerk-7
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017925A1 (en) * 1994-12-06 1996-06-13 Immunex Corporation Cytokine designated lerk-7
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] 12 January 1996 (1996-01-12) Database accession no. N31410 XP002209892 *
DATABASE EMBL [Online] 12 January 1996 (1996-01-12) Database accession no. N31809 XP002209891 *
DATABASE EMBL [Online] 15 March 1996 (1996-03-15) Database accession no. N67726 XP002209890 *
JACOBS K ET AL: "A NOVEL METHOD FOR ISOLATING EUKARYOTIC CDNA CLONES ENCODING SECRETED PROTEINS" , JOURNAL OF CELLULAR BIOCHEMISTRY - SUPPLEMENT, WILEY-LISS, US, VOL. 21A, PAGE(S) 19 XP002027246 ISSN: 0730-2312 * the whole document * *

Also Published As

Publication number Publication date
CA2291260A1 (en) 1998-12-10
EP1039801A4 (de) 2003-03-26
WO1998054963A2 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
EP1039801A1 (de) 207 menschliche sekretierte proteine
US6590075B2 (en) Secreted protein HODAZ50
US6569992B1 (en) Protein HLQDR48
US20030060619A1 (en) Secreted protein HFEAF41
US6342581B1 (en) Secreted protein HLHFP03
WO1998039448A9 (en) 186 human secreted proteins
WO1998042738A9 (en) 87 human secreted proteins
US20030077809A1 (en) 97 human secreted proteins
US6531447B1 (en) Secreted protein HEMCM42
US20030055236A1 (en) Secreted protein HKABT24
US20030045459A1 (en) 67 Human secreted proteins
CA2302808C (en) 50 human secreted proteins
US20040002066A1 (en) 36 human secreted proteins
WO1998056804A1 (en) 86 human secreted proteins
US20020164669A1 (en) Secreted protein HRGDF73
US6433139B1 (en) Secreted protein HPEAD48
US6806351B2 (en) Secreted protein HBJFE12
US20030105297A1 (en) Secreted protein HEMCM42
US6410709B1 (en) Cornichon-like protein
US20030144492A1 (en) 101 human secreted proteins
US20030176681A1 (en) 148 human secreted proteins
US20030166906A1 (en) 50 human secreted proteins
US20030211472A1 (en) 125 human secreted proteins
EP1042346A1 (de) 86 menschliche sekretierte proteine
EP0972030A2 (de) 70 humane sekretierte proteine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030207

17Q First examination report despatched

Effective date: 20030721

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040201

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CARTER, KENNETH

Inventor name: ENDRESS, GREGORY

Inventor name: DILLON, PATRICK

Inventor name: FENG, PING

Inventor name: YU, GUO-LIANG

Inventor name: KYAW, HLA

Inventor name: ZENG, ZIZHEN

Inventor name: LI, YI

Inventor name: SOPPET, DANIEL

Inventor name: FISCHER, CARRIE

Inventor name: WEI, YING-FEI

Inventor name: FAN, PING

Inventor name: NI, JIAN

Inventor name: LAFLEUR, DAVID

Inventor name: FLORENCE, KIMBERLY

Inventor name: FLORENCE, CHARLES

Inventor name: SHI, YANGGU E

Inventor name: MOORE, PAUL, A.

Inventor name: BREWER, LAURIE, A.

Inventor name: EBNER, REINHARD

Inventor name: OLSEN, HENRIK

Inventor name: HU, JING-SHAN

Inventor name: ROSEN, CRAIG

Inventor name: RUBEN, STEVEN

Inventor name: FERRIE, ANN, M.

Inventor name: GREENE, JOHN

Inventor name: YOUNG, PAUL